Rockefeller University

Digital Commons @ RU
Student Theses and Dissertations

2012

Structure Function Analysis of Adenosine
Deaminase Acting on tRNA (ADAT2) from
Trypanosoma Brucei
Miller Marshall

Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
Recommended Citation
Marshall, Miller, "Structure Function Analysis of Adenosine Deaminase Acting on tRNA (ADAT2) from Trypanosoma Brucei"
(2012). Student Theses and Dissertations. Paper 168.

This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.

STRUCTURE FUNCTION ANALYSIS OF ADENOSINE DEAMINASE
ACTING ON TRNA (ADAT2) FROM TRYPANOSOMA BRUCEI

A Thesis Presented to the Faculty of
The Rockefeller University
in Partial Fulfillment of the Requirements for
the degree of Doctor of Philosophy

by
Marshall Miller
June 2012

©Copyright by Marshall Miller 2012

STRUCTURE FUNCTION ANALYSIS OF ADENOSINE DEAMINASE
ACTING ON TRNA (ADAT2) FROM TRYPANOSOMA BRUCEI
Marshall Miller, Ph.D.
The Rockefeller University 2012

tRNA is edited at the wobble position of the anticodon to accommodate the degeneracy
of the genetic code. The enzymes responsible for deamination of adenosine 34 to inosine
are found in all organisms and in all but a few cases are essential for life. In bacteria the
reaction is carried out by the homodimeric adenosine deaminase acting on tRNA (ADAT)
and modifies only tRNAarg, whereas in eukarya the enzyme is the ADAT2/3 heterodimer,
which performs the same reaction on all tRNA molecules with adenosine at position 34.
Despite a similar evolutionary origin, the characteristics of these two enzymes are
significantly different. Substrate binding and catalysis occur within the active site of the
bacterial homologue, which can act on both stem-loop substrate analogues and full-length
tRNA. Eukaryotic heterodimers function differently with separate substrate recognition
and enzymatic components and are only active on full-length tRNA. Furthermore, in
trypanosomatids, the ADAT2/3 complex has been shown to also exhibit C-to-U
deamination in vitro, and the ADAT2 protein alone has been shown to play a role in Cto-U editing in vivo at the C32 position of tRNA. The basis for these extra enzymatic
activities is unknown. ADAT2 homodimers from trypanosomes and humans have been
shown to be stable in vitro but these homodimers show dramatically decreased tRNA
binding and have no detectable enzymatic activity toward the typical tRNA substrates.
While crystallographic data exist for the human ADAT2, the structural underpinnings for
both the lack of canonical enzymatic activity and the acquisition of additional

functionality in the trypanosomatid enzymes remain unanswered. In the presented work
xray crystallography was used to determine the structure of ADAT2 from T. brucei. The
solution of the structure was technical, requiring several different crystallographic
techniques at each step of the process. These are described in detail. The final structure
revealed an enzyme harboring the canonical cytidine deaminase fold and an otherwise
normal functional-appearance with no obvious indications as to why this enzyme is
inactive. Potential reasons for the loss of substrate binding were indicated by mutations in
the regions of ADAT2 analogous to the bacterial enzyme. Further analysis identified
three loop regions that are unique to trypanosomatid ADAT2 and are located in regions
of structural significance so as to suggest a mechanism for an altered substrate profile for
this orphan enzyme.!
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Chapter 1 Introduction
The severe impact of Trypanosoma spp. on Sub-Saharan Africa and South America
cannot be overstated. Trypanosomiases are serious diseases with significant morbidity
and mortality not only to humans but also to their domesticated animals resulting in
devastating health and economic consequences.1, 2 These concerns in addition to the
complex and fascinating virulence mechanisms exhibited by these parasites have
interested researchers in many fields of biology, medicine and even politics for more than
a century.3
T. bruceii contain two subspecies that cause African trypanosomiasis (commonly,
sleeping sickness) in humans: an acute form by T. b. rhodesiense in eastern and southern
Africa, and a chronic form by T. b. gambiense in western and central regions of the
continent. The African Union has been joined by the World Health Organization in its
efforts to eradicate African trypanomiasis through a variety of techniques, but the
complexity of the natural reservoir of these parasites combined with the geopolitical
challenges of the region do not foretell complete eradication.4 Similar efforts have been
underway in Central and South America to control T. cruzii, which causes American
trypanosomiasis (commonly Chagas disease), a chronic disease that if left untreated leads
to life threatening gastro-intestinal and/or cardiac conditions.5 Despite the efforts to
control the parasite and its vectors, the primary tool for the control and management of
these diseases remains chemotherapeutic treatment, yet the development of new
compounds beyond the basic science level has seen a dearth of both interest and funding,
something that the Drugs for Neglected Diseases Initiative of the Gates Foundation aims
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to specifically address.6 Regardless, the search for new and more narrowly defined drug
targets remains a significant motivator for the continued study of these parasites.
In addition to the health and economic concerns, Trypanosoma offer well-suited model
systems to explore many questions at the vanguard of immunology, cell-, and molecular
biology. While unique and highly adapted to several very specific biological niches,
these organisms share a significant amount of cellular machinery with higher eukarya.
Modulation of host immunity, the gene regulation of antigenic variation, epigenetic
regulation, and post transcriptional gene regulation are all examples of recent reviews
highlighting active areas of research in the Trypanosome field that involve or pertain to a
broad swath of the higher eukarya.7-9 Now with the complete genome sequence of T.
brucei, even more tools will be available for application to these fields of study.10
Trypanosoma have been an area of intense interest to those studying gene regulation and
RNA editing as these organisms harbor several examples of very unique biology.
Trypanosoma belong to the class Kinetoplastida, so named for the kinetoplast, a large
collection of circular DNA found within the single mitochondrion present in these
organisms. The kinetoplast genome contains roughly a dozen large circular DNA
molecules called maxi-circles harboring the typical genetic information of mtDNA and
also contain thousands of interlocking mini-circles harboring a variety of genetic
elements. The field of RNA editing was founded with the discovery in 1986 that a
kinetoplast-derived mRNA transcript for CoxII from T. brucei was modified posttranscriptionally to generate a frame shift and eliminate an early stop codon.11 The
mechanism for this type of editing was discovered a few years later when Sturm and
Simpson identified small genes they termed guide RNAs on the mini-circles of
!
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kinetoplasts which formed templates by which the mRNA of the maxi-circles were
subsequently edited.12
Within the nuclear genome, Kinetoplastida also exhibit a thymidine modification that is
unique to Kinetoplastida and Euglena, which has been shown to exhibit several
hallmarks of epigenetic regulation.13 This hypermodified thymidine – β-dglucopyranosyloxymethyluracil – is known as base J and has been identified primarily in
telomeric regions across Kinetoplastida genomes. In varying degrees base J has also
been found in sub-telomeric and/or repetitive DNA sequences in some genera of the
class.14 The formation of base J is a conserved two-step process putatively involving J
Binding Proteins 1 and 2 (JBP1/2) and an unidentified glycosyl transferase (GT);
however, a conserved mechanism of function for base J remains elusive as have the rules
governing initial base J modification, maintenance, and elimination . Data showing both
an increase in base J content during the mammalian-host phase of the Trypanosoma life
cycle and an association of base J content with the variable surface glycoprotein (VSG)
repeats in the Trypanosoma genome – a family of genes that are variably regulated to
affect host immune evasion – have generated significant interest in the possibility that
base J in part regulates surface antigen display and variation; however, JBP1-null/JBP2null mutations in T. brucei did not effect viability in either the insect or the mammalian
phase of infection.15 Opposite results wherein JBP1-null mutations are lethal in
Leishmania, where more than 98% of base J is telomeric, further complicating the a
unified function for base J in Kinetoplastida.16, 17 A possibility remains that parasitespecific chemotherapy targeting this pathway could prove effective, particularly in the
case of Leishmania; however, significant advances in the field will be necessary for such
!
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an approach to become viable. Specifically the regulation of the base J modification
pathway is still poorly understood and the role of other factors in addition to JBP1 and 2
cannot be eliminated. While the absence of base J may not compromise
Trypanosomatids, the disregulation of the pathway could prove an effective
chemotheraputic approach
The genetic organization of trypanosomatids at the chromosome level in the nucleus also
highlights the degree to which these organisms differ from other eukarya with regard to
gene regulation. A significant portion of the Trypanosoma genome is transcribed in
polycistronic operons that contain multiple genes belonging to unrelated metabolic and
cellular functions.18 This type of organization then requires a novel type of gene
regulation that takes place to a large degree at the level of RNA processing and editing,
making trypanosoma and other kinetoplastida ideal organisms in which to study the
process of RNA editing.
There are many ways in which RNA is modified post-transcriptionally. Many of these
modifications are best classified as RNA processing and include events such as splicing,
capping and polyadenylation. In contrast, RNA editing is the modification of the genetic
code through selective enzymatic modifications to specific nucleotides resulting in an
RNA molecule that is not just rearranged but actually different from the DNA sequence
from which it came. A fascinating example of this type of editing occurs in the anticodon
stem-loop domain of tRNA and will be the focus of the discussion to follow.
The role of inosine in the wobble position of the tRNA anticodon was proposed more
than 45 years ago by Crick to explain the degeneracy of the genetic code.19 tRNA
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molecules with an inosine in this position are able to translate codons ending in U, A, or
C. (Figure 1.1 B) This strategy provides a significant portion of the solution to the
problem of translating the 61 codons of the genetic code using no more than 40 tRNA
genes, and is essential for life in both prokarya and eukarya.20

Figure 1.1 The generation and wobble base pairings of inosine in tRNA. A. Reaction
mechanism for deamination of adenosine to inosine by ADAT from Luo et al.21 B.
Wobble base pairing showing the ability of inosine to pair with adenosine, uracil, or
cytosine the additional ability of guanine to pair with uracil
Adenosine Deaminases Acting on tRNA (ADAT) in bacteria and plants edit A-to-I at the
wobble position (position 34 of the anticodon) only in tRNAArg (these proteins are also
know as tRNA Adenosine Deaminase Arginine, or TADA) whereas in higher eukaryotes
this editing occurs in all eight codons (seven in yeast) with an adenosine at position 34 of
the anticodon.22 In bacteria and plants, TADA is active as a homodimer; however, in
higher eukaryotes a heterodimer of ADAT2 and ADAT3 is necessary for activity.23, 24
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Gerber et al. have shown that a sequence analysis of these proteins suggests an
evolutionary relationship such that ADAT 2 and 3 are paralogues of the original TADA
genes 23, which later evolved the necessary mechanisms to accommodate multiple tRNA
substrates. Further evidence for this argument is provided by the fact that original studies
on yeast ADAT2/3 showed activity toward E. coli tRNA, but the converse was not true:
E. coli ADAT would only modify tRNA with the arginine anticodon ACG.25 The
evolutionary relationship between these enzymes is of significant interest as it suggests a
relationship wherein ADAT2 and ADAT3 found in lower eukaryotes could provide
significant insight into the origin and function of cytidine deaminases in higher eukarya.
Activation Induced Cytodine Deaminase (AID) and the Apo-lipoprotein B mRNAediting enzyme catalytic polypeptide (APOBEC) family of enzymes are members of the
cytidine deaminase family that have been intensely studied for their roles in epigenetic
regulation and DNA repair in higher vertebrates; however, a structural understanding of
their function is still incomplete and awaits they type of detail that has been elucidated in
the prokaryotic enzymes and is beginning to be established for ADAT2/3 in lower
eukarya.
These proteins all belong to the large Cytidine Deaminase (CD) superfamily of enzymes.
Members of this family all perform similar deamination chemistry on a variety of
substrates including nucleotides, nucleosides, small-molecule metabolites, tRNA,
dsRNA, and DNA. The signature sequence of the superfamily, H/C-X-E…PCXXC,
contains three resides that coordinate a tetrahedral zinc ion (two cysteines and a histidine,
or three cysteines). The fourth ligand to the zinc is an activated water molecule that
performs the nucleophilic attack on the carbon atom that is being deaminated. Proton
!
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extraction by the glutamate in the above motif results in oxidation of the hydroxyl and
release of ammonia. (Fig. 1.1 A)
The conserved core fold of the cytidine deaminase superfamily has been identified by
sequence and structure analysis. The fold consists of a 5-strand β-sheet core sandwiched
on either side by α-helix bundles – a two-strand bundle on one side, and a three-strand
bundle on the other. The three-strand α-helix bundle contains the residues of the zinc
binding motif as well as a majority of the residues involved in the most commonly seen
dimerization interface. The quaternary structure varies across the superfamily, and a
variety of subunit conformations have been shown or proposed including putative
monomers, homo-dimers, homo-trimers, tetramers, and as in the case of ADAT2/3,
heterodimers. The ADAT enzymes at the core of this discussion have all been shown to
exist as either homo- or hetero-dimers with an interface created by the same helicies that
contain the active site zinc as described above. (Figure 1.2 A-B)
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Figure 1.2 The core cytidine deaminase fold as exemplified in the ADAT family of
enzymes. A. Topology of the α-helices (red) and β-sheets (blue), dimerization interface,
and zinc coordination for ADAT B. Alternate orientation that has been described for
APOBEC2. C. Active site of saADAT2 (monomers A and B are red and cyan) bound to
tRNA substrate analogue (blue). D. Alignment of the tRNA anti-codon step loops in the
native (gray) and saADAT-bound (blue) conformations showing the splaying out of the
bases induced by substrate binding, specifically at bases 34-37 of the anticodon loop.
Figures A and B from Silvestro et al.26, C and D from Losey et al.27
Multiple crystal structures of bacterial ADAT homologues have been reported, as has the
structure of the human ADAT2 homodimer (hsADAT2) all at medium to high
resolution.27-32 Structural and sequence alignments of these homologues show a very
!
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highly conserved core fold with r.m.s. values between 1.2-1.5Å. All structures to date
show a consistent quaternary structure comprising a homodimer with each monomer
related to the other by a rotational axis of symmetry parallel to the dimer interface.

This

orientation generates two equivalent active sites on opposite faces of the protein with
each monomer contributing to each site. The structural basis for tRNA binding in
bacterial ADAT has been demonstrated via the co-crystalization of S. aureus TadA
(saADAT2) with a non-hydrolyzable step-loop tRNA substrate analogue.27 (Figure 1.2 C)
This structure demonstrates how tRNAarg recognition is accomplished primarily through
sequence-specific interactions that clearly discriminate for the tRNAarg anticodon
sequence and seems to rely very little on non-specific structural elements within the
tRNA molecule. tRNA binding to saADAT2 induces a conformational change in the
tRNA molecule such that the anticodon bases are splayed out facilitating sequencespecific interactions with highly conserved saADAT2 residues, but interestingly, there is
only minimal structural change in saADAT induced upon substrate binding compared to
other bacterial homologues. (Figure 1.2 D) Interestingly, the structure suggests that the
histidine participating in the zinc-coordination is also critical in providing important
sequence specific contacts to A34. The structure highlights the fact that few non-specific
interactions occur between the protein and the stem-loop RNA and suggests that the
predominant characteristics of substrate binding in bacterial ADATs relate to the
anticodon loop and are sequence specific. Additional analysis of the substrate-bound
saADAT2 reveals two equivalent binding sites per dimer with very minimal change
relative to other structures of bacterial ADAT without substrate, which suggests this
enzyme lacks significant allosteric or coopertive substrate regulation. Given the nature
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of the stem-loop used for crystallization in the saADAT structure, the conclusions drawn
from this structural analysis are preliminary and await further data with full-length
substrate. Of particular interest is the degree to which the remainder of the tRNA
interacts with ADAT, how exactly that interaction is shared between the two monomers
of the functional homodimer, and to what degree those interactions confer any type of
specificity.
Of the five ADAT structures to date, none have been able to show ordered density in the
most C-terminal region of ADAT, which has been shown biochemically to interact with
tRNA in ADAT2/3 and, based on the saADAT-tRNA structure, would be oriented
adjacent to the bound tRNA molecule. The precise nature of the interaction between
tRNA and these unstructured regions of ADAT is relatively unknown. This interaction
has been shown to be critical for activity in both prokaryotic ADAT and eukaryotic
ADAT2/3; however, biochemical data indicate that there are potential differences in the
function and importance of this region. Elias et al. have demonstrated that truncation of
the 8 C-terminal residues in A. tumefaciens ADAT (atADAT) decreases enzymatic
activity toward both a stem-loop and a native tRNAarg substrate by 2000-fold.31 Similarly,
C-terminal deletions as well as specific point-mutations in a C-terminal lysine-rich
domain in the eukaryotic T. brucei ADAT2 (tbADAT2) have been shown by Ragone et
al. to significantly affect binding and catalysis of tRNA substrates in the context of the
tbADAT2/3 heterodimer 33; however these authors also note several differences between
tbADAT2/3 substrate binding and that of saADAT. They have noted several nonconservative mutations in residues of the tbADAT2 sequence that align to residues
required for tRNAarg binding in the saADAT structure described above, and they have
!
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reported that tRNA binding in tbADAT2/3 is unaffected by single alanine pointmutations to conserved residues in tbADAT2 that align to residues important for tRNAarg
binding in the saADAT structure. For example, whereas E92 is makes important contacts
to tRNAarg in saADAT, E92A in tbADAT2/3 does not affect substrate binding.
Furthermore, in ADAT2/3 from T. brucei and S. cerevisiae it has been shown that the
eukaryotic tRNA deaminases require full-length substrates and cannot catalyze the stemloop analogues used for much of the biochemical characterization of the bacterial ADAT
enzymes 23, 25, 31, 33, which suggests that although critical in both prokaryotic and
eukaryotic ADAT, the specific nature of the interaction between the C-terminal tail and
the full tRNA molecule also seems altogether different in the two groups of ADAT.
These results indicate that both bacterial and eukaryotic ADATs utilize regions of the Cterminus to facilitate binding and/or catalysis, but they also demonstrate how there is a
significant divergence in substrate binding behavior both within the active site with
regard to sequence-specific substrate binding and outside the active site with regard to the
size and nature of the substrate being recognized. These results point to many of the gaps
in our understanding of the different mechanisms of action across the family of ADATs
and how these differences could account for the narrow versus broad substrate profiles
exhibited by the prokaryotic and eukaryotic homologues, respectively. Many questions
on this topic remain. Among them, why is the C-terminus important for catalysis – is it
substrate affinity alone, or possibly an induced fit mechanism? What is different about
narrow versus broad substrate recognition? Are the differences due to a different active
site alone or to additional factors outside the active site? As will be discussed below,
what is the contribution of ADAT3 and does this account for some of these differences?
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The core fold of these enzymes has not been shown to change significantly between the
substrate bound and unbound states, and as mentioned above, the c-terminus has not been
ordered in any of the homologous structures to date. How this crystallographically
disordered region participates in substrate recognition and catalysis remains to be seen.
One likely explaination would be a conserved feature within the substrate tRNAs for the
eukaryotic heterodimers – either a specific sequence or motif – that could that would
prove essential for substrate recognition thus allowing the eukaryotic enzymes to screen a
larger set of molecules for a compatible anti-codon sequence on which to perform
chemistry. Direct evidence for such a mechanism will require a more detailed
understanding of the eukaryotic ADAT2 and ADAT3 enzymes and is one of the
motivations for the studies initiated below. To date only the human ADAT2 structure has
been reported in the protein data bank and there remains a paucity of structural data for
the ADAT3 protein.
As mentioned above, the formation of an ADAT2/3 heterodimer is essential for A-to-I
activity in both yeast and trypanosomes and both ADAT2 and ADAT3 are necessary and
essential for this activity.23, 24 The features of this heterodimer in T. brucei have been the
focus of significant biochemical characterization in by the Alfonzo group at Ohio State
University, which has revealed that tbADAT2/3 exhibits exhibits the expected A-to-I
editing all tRNA with A34 in the wobble position of the anti-codon, but in addition they
have identified a much wider substrate profile in addition to additional enzymatic
activity.
The most striking observation thus far is the ability of tbADAT2/3 to perform C-to-U
editing on DNA substrates in vitro as well as evidence that ADAT2 plays a role in C-to-U
!
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editing on C32 of tRNA in vivo 24, which stimulates additional A34-I editing of the
anticodon.34 The ability to deaminate cytosine and adenosine is unique to the
trypanosomatid enzymes and has not been reported for any other members of the CD
superfamily, raising the possibility that ADAT2/3 represents an evolutionary step
between the A-to-I editing enzymes and the C-to-U editing enzymes. In higher
eukaryotes the search for demethylases involved in epigenetic regulation has identified
Activation Induced cytidine Deaminase (AID) as a potential candidate. The purported
mechanism of AID entails methyl-cytidine to uridine deamination, which then prompts
removal of the methyl-uridine via mismatch repair resulting in unmethylated C at the
same position.35 The hypothesis that ADAT2/3 is an evolutionary precursor to AID is not
supported by a genetic analysis 36; however the likelihood that both families evolved
similar solutions to the same enzymatic problems remains possible. Certainly the
relationship between these families will be an area of future interest. Methylases have
been identified in T. brucei that will allow this question to be probed in much greater
detail as it is expected to soon be possible to generate the 3-methyl-cytosine substrates
that are essential for epigenetic regulation in higher eukaryotes. Such substrates, whether
tRNA or DNA, will then be available for biochemical analysis with ADAT2/3 to more
completely understand the link between methylation and deamination that early evidence
has indicated. Specifically, it has recently been shown that the C/U32 base is
methylated in T. bruci (Alfonzo, unpublished). This result together with the evidence
that ADAT2 plays a role in C-to-U editing at this position raises the interesting
possibility that ADAT2/3 editing is linked to methylation. This result parallels the
activity of ADAT1 that has been shown to deaminate A-37 of the anticodon loop, which
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is subsequently methylated by an unknown mechanism.22 Similar to the suggestions
above, ADAT1 has also been suggested as an ancestral precursor to the eukaryotic
adenosine deaminase acting on RNA (ADAR) family of enzymes.37 The adaptation of
the cytidine deaminase fold to many of the biochemical tasks of cell biology is a broad
field and will by no means be sufficiently explained by one or two key crystal structures.
Rather it is a field that is advancing as examples of each type enzymatic activity is
investigated in relation to each of the various substrates acted upon by these enzymes. A
significant appeal, therefore, is found in the ADAT2/3 enzyme in T. brucei as it would
provide a look at an enzyme that has been shown to be involved in several different
enzymatic activites on methylated substrates, which is a field that is being actively
investigated but has yet to yield significant structural results.
A striking difference between the bacterial and eukaryotic ADAT enzymes involves the
architecture of the active site and the necessity for an ADAT2/3 heterodimer. Secondary
structure predictions and computational modeling suggest ADAT3 exhibits the same
cytidine deaminase fold as ADAT2, and consequently is predicted to form a dimer with
an orientation and interface similar to the prokaryotic homodimer.38 This orientation
raises several questions since the two identical biding sites observed in the bacterial
ADATs would no longer be equivalent in the heterodimer, i.e. the zinc binding site of
ADAT2 would open toward a surface created in part by ADAT3, and the reciprocal
active site in ADAT3 would open towards a surface created in part by ADAT2 that could
potentially be completely different. Additionally, the HxE…CxxC motif is mutated in
eukaryotic ADAT3 with a Glu-Val mutation at the key catalytic glutamate.22 Since the
histidine and two cysteines required for zinc coordination were present in this sequence,
!
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it was generally accepted that ADAT2/3 heterodimers contained two zinc ions, one in
each monomer, and that only the ADAT2 zinc was catalytically active.23 Spears et al
have recently called this assumption into question through a series of mutagenesis studies
demonstrating that the zinc-coordinating cysteines of ADAT2 were not essential for
either substrate binding or activity whereas ADAT2 glutamate and the equivalent
ADAT3 cysteines were essential for enzymatic activity. As a potential explaination for
this data, the authors have proposed a domain-swapped model in which the HxE motif of
ADAT2 combines with the CxxC motif of ADAT3 to form a complete active site.38 A
domain-swapped heterodimer would still exhibit two different active sites, one
comprising the essential glutatmate 92 from ADAT2 with the essential zinc coordinating
cystines from ADAT3. The precedent of a domain swap in a member of the CD
superfamily has been shown in B. subtilis guanosine deaminase in which one β-strand
and the terminal α-helix of one monomer exchange in a symmetrical fashion with the
other protomer of the dimer pair.39 In the case of ADAT2/3, the proposed swap would be
more significant and entail an exchange of 3 β-strands and 2 helicies, essentially one half
of the ADAT2 protein. (Figure 1-3 A and B )
The results of Spears et al. have modified the understanding of ADAT2/3 in several
significant ways: they confirm a role for ADAT3 in catalysis, they demonstrate a 1:1
stoichiometry (tRNA:dimer) as opposed to 2:1 in bacteria, and they provide evidence for
an intricate interplay between ADAT2 and ADAT3 to form a shared catalytic zinc site. It
is worth noting that these results do seem to conflict to a degree with other results
mentioned above regarding the importance the ADAT2 C-terminus. This so-called KRdomain of ADAT2 (for its amino acid sequence KRKRK) has been shown to be essential
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for tRNA binding and catalysis 33; however, an analysis of the domain swap structure
would suggest that the C-terminus of ADAT2 in the domain-swapped model is positioned
on the opposite side of the dimer from the putative active site. (Figure 1-3 B) How these
models will evolve under the light of further scrutiny remains to be seen.

Figure 1-3. Proposed configurations for T. brucei ADAT2/ADAT3 heterodimer (blue
and maroon, respectively with zinc ions depicted as pink spheres) from Spears et al.40
ADAT2 is modeled from the saADAT crystal structure and ADAT3 is modeled from an
ab initio simulation. A. Non-swapped heterodimer where the HxE and CxxC motifs for
ADAT2 (red) and ADAT3 (green) coordinate the zinc ion of the respective monomer. B.
Domain swapped orientation that generates one zinc-coordination site (on the left in B)
containing the HxE of ADAT2 and CxxC of ADAT3, which is accessible from the top of
the molecule in this orientation, directly adjacent to the C-terminus of ADAT3.
One final discovery that has been observed along-side the developments in ADAT2/3
biochemistry has been the identification of a stable species in vitro of a tbADAT2
homodimer 38, which is consistent with the recent crystal structure of hsADAT2. There
has been very little characterization of these eukaryotic ADAT2 homodimers. Based on
the hsADAT2 crystal structure (PDB:3DH1), they share a common fold and domain
architecture with bacterial ADAT; however, the tbADAT2 sequence shows several
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distinct insertions relative to hsADAT2 that have remained uncharacterized and could
provide interesting alternate substrate profiles (discussed below).
Binding of tRNA substrates has been reported for tbADAT2 homodimer that is one to
two orders of magnitude lower than for the tbADAT2/3 heterodimer; however, no in vitro
A-to-I activity has been detected in tRNA substrates by tbADAT2 in the absence of
ADAT3, despite extensive incubations under saturating conditions.38 This result has
prompted speculation that inactivity is not due simply to low affinity but may involve
structural reorganizations involving, for example, incorrect zinc-coordination in the
homodimer and/or occlusion of the active site, which are somehow rescued by ADAT3
through heterodimer formation, perhaps through the domain-swap mechanism discussed
above. The presence of a stable tbADAT2 homodimer that is inactive toward tRNA
substrates raises many interesting possibilities and provides an important tool with which
to study the increased complexity observed when moving from prokaryotes to
eukaryotes, particularly in regard to the involvement of ADAT2 in potential methylation
pathways in T. brucei. Given that ADAT3 rescues the inactivity of the tbADAT2
homodimer toward tRNA, an interesting question is whether there are features of
tbADAT2 that have been lost, so to speak, in comparison to bacterial ADAT and what
specifically these differences reveal about the rules for substrate binding in the ADAT2/3
heterodimer. An analysis of the human ADAT2 structure reveals a dimer interface nearly
identical to those observed in bacterial ADAT suggesting there is no clear impediment
for the same tbADAT2 dimer seen in vitro to also exist in vivo; however, the function of
this dimer remains unknown. Perhaps the tbADAT2 homodimer is simply a reservoir for
the ADAT2/3 heterodimer and that transition between the homo- and hetero-dimer forms
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allows some level of regulation of activity within the cell. Evidence that ADAT2 is
involved in C-to-U editing in DNA and also is involved in potential methylation
pathways suggests the intriguing possibility that tbADAT2 as a homodimer is not
inactive so much as the actual substrate has yet to be identified. In losing activity toward
tRNA perhaps tbADAT2 has opened the possibility to act on DNA or other types of
RNA. The role of the tbADAT2 homodimer will be important to determine in order to
further the understanding of the role this enzyme plays in the biology of T. brucei and
other higher eukaryotes.
As an initial step to address the questions raised above, the following discussion presents
the structure of tbADAT2 by means of x-ray crystallography. Chapters describing the
results from the major phases of the project are as follows: 2, materials and methods; 3,
protein purification; 4, crystal optimization and data collection; 5, structure
determination; and 6, structure analysis, in which the tbADAT2 homodimer reveals
several interesting characteristics that show a departure from the typical structural
features of known homologues. Chapter 7 will discuss the implications of the finding
that the ADAT2 structure reveals no clear mechanism of enzymatic inactivity and could
provide several possible mechanisms of alternate substrate specificity.

!

18

Chapter 2: Materials and Methods
Protein purification
Recombinant N-terminal 6xHis-tagged tbADAT2 (C117S) was expressed off a modified
pET28 (6xHis-3C-AUG) vector in BL21 RIL (Stratagene) cells as follows: 16 x 1.5 L
cultures of bacteria were grown at 37°C in Luria Broth to an OD600 of 0.5-0.8 and induced
at 0.5 mM IPTG for 18 hours at 18°C. Cells were harvested by centrifugation,
resuspended in 100-120 mL of resuspension buffer (20 mM HEPES pH 7.6 @4°C, 200
mM NaCL, 20 mM Imidazole, and 20 mM β-mercaptoethanol) and lysed via Emulsiflex
(Avestin) until sample was no longer viscous. Cleared lysate (25,000xg) was filtered
(0.65 µ) and loaded onto a 14 ml Ni-NTA (Quiagen) column equilibrated in resuspension
buffer. The loaded column was washed with 10 column volumes (CV) of resuspension
buffer and bound protein was eluted by a linear imidazole gradient (20-500 mM
imidazole in resuspension buffer) over 8 CV. Fraction contents were visualized via SDSPAGE, pooled, and dialyzed overnight with 3C protease in dialysis buffer (20mM
HEPES pH 7.6 @4°C, 200 mM NaCl, and 5 mM DTT). Following dialysis, the protein
sample was diluted to 100 mM NaCl with Buffer A (20 mM HEPES pH 7.6, 5 mM DTT)
and loaded on a 1.0 mL Hi-Trap Heparin Agarose FPLC column (GE Lifesciences)
equilibrated in 2.5% buffer B (20 mM HEPES pH 7.6 at 4°C, 2.0M NaCl, 5mM DTT).
The loaded column was washed with 10 CV 2.5% buffer B and bound protein was eluted
by a linear NaCl gradient (2.5-25% buffer B) over 40CV. Fraction contents were
visualized via SDS-PAGE and desired fractions were pooled, spin concentrated (30 kDa
Amicon Ultra), and further purified first with Superdex 200 16/60 and then with
Superdex 75 16/60 gel filtration (GE Healthcare).
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Crystallization
Purified tbADAT2 was concentrated to 100-110 mg/mL by spin concentration (30 kDa
Amicon Ultra) and crystallized at 4°C in 2-4 µL drops in 1:1 ratio with a well solution
(WS) of 944 mM K/Na tartrate, 200 mM LiSO4, and 100 mM HEPES pH 6.9 via hanging
drop vapor diffusion (total well volume 1.0 mL) for 2-3 weeks. Crystals were cryo
protected using 20% glycerol or dehydration and flash cooled by plunging into liquid
nitrogen (LN2): crystals were incubated in WS containing increasing glycerol
concentration (5% increments to 20%, 2 minutes per step); or crystals were dehydrated
12-16 hrs in 10 µl drops comprised 1:1 of WS:WS with saturated with Na/K tartrate
(WS-sat) by vapor diffusion over 1.0 ml WS-sat, and then further dehydrated by allowing
the drop to evaporate 5-6 minutes (just before the formation of salt crystals) and then
flash cooled as above. Crystals were stored in LN2 until data collection.
Data Collection
Crystals were screened for quality assessment and successful cryo-protection using an inhouse Raxis-IV++ rotating Cu-anode x-ray source, and complete native and Zn-SAD
datasets were collected on beamline X-29 at Brookhaven National Synchrotron Light
Source (NSLS) at wavelengths of 1.0750Å (360° by 1° oscillations, 1.0 s exposures, )
and 1.2826Å (360° by 1° oscillations, 2.0 s exposures), respectively, utilizing a robotic
auto-mounter for high sample throughput and a ADSC-Quantum 315r CCD detector.
The wavelength for the Zn-SAD dataset was determined empirically using CHOOCH to
analyze the X-ray fluorescence spectra from a representative tbADAT2 crystal.41 All data
were collected at LN2 cold-stream temperatures (~110K).
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Structure Determination
Diffraction data were indexed, integrated, and scaled using HKL2000.42 Asymmetric unit
contents were estimated using Matthew’s coefficients.43, 44 Molecular replacement,
phasing, and initial model building were performed using AutoMR, Auto-Sol, and
AutoBuild, respectively in PHENIX (Python based Hierarchical ENvironment for
Integrated Xtallography)45, followed by rounds of manual model building and refinement
in COOT46 and REFMAC547, with additional application of anisotropic scaling48 and TLS
refinement.49 The final protein data bank (pdb) files resulting from TLS refinement were
analyzed with TLSANL50 to recover thermal B-factors. Molecular replacement search
models for tbADAT2 were created with the program CHAINSAW51 in CCP452 using the
hsADAT232 as a starting model. Additional model building for unstructured loops was
attempted with ARP/wARP53 and fit_loops in PHENIX. Overall structural stastics
including rotomer, Cβ-, geometric, and ramachandran analyses were performed during
model building in COOT and following refinement using MOLPROBITY54 and
ERRAT.55 Structural analyses were conducted with SWISS-Pdb Viewer56, COOT, and
CCP4mg57 as well as using web servers DALI58, PHYRE59 and ERRAT55 for structural
comparisons and homology searches, and ESBRI60 for identifying salt bridges in the
structure.
Disulphide cross-linking
The final structure of tbADAT2 was used to model the ADAT2/ADAT3 heterodimer.38
The webserver Disulphide by Design ®61 was used to analyze both the tbADAT2
homodimer and ADAT2/3 heterodimer for permissive sites to introduce cysteine point
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mutations for the formation of engineered disulfide bonds. These mutations were then
modeled using CCP4mg57 to determine which cysteine pairs would give definitive SDSPAGE mobility shifts as described by Sorensen et al.62
Site-directed mutagenesis

Forward Primer
Reverse Primer
dNTP mix
Buffer (10X)
Template DNA
Polymerase*
ddHOH
Incubation (°C)
Melting (°C)
Annealing (°C)
Extension (°C)
Cycles
2° Annealing °C
2° Extension°C

Single AA substitution

Insert Mutagenesis

Sub-cloning/LIC

0.5 µl 2.5 pmoles/µl

1.0 µl of 50 µM

1 µl 50 µM

0.5 µl 2.5 pmoles/µl

1.0 µl of 50 µM

1 µl 50 µM

1.25
µµ µl (2.5 mM each dNTP)
1.25 µl PFU Buff. (Stratagene)

5 µl of 2.5 mM

2 µl 25 mM

5 µl PFU Buff. (Stratagene)

10 µl Thermopol (NEB)

1.0 µl (2ng/µl) miniprep DNA

2-10 ng miniprep DNA

50-90ng miniprep DNA

0.25 µl PFU (Stratagene)

1 µl PFU (Stratagene)

1 µl Deep Vent (NEB)

to 12.5 µl

To 50 µl

to 100 µl for 2 reactions

95° 5’

95° 5’

95° 5’

95° 1’15’

95° 1’15’

95° 30”

Tm of Primer - 5°C

Tm of Primer - 5°C

56°

68° 1’ + 1’/1kb

68° 1’ + 1’/1kb

72° 1’30”

20-22

12-25

25-35

Tm -5°C

Tm -5°

N/A

68° 10’

68 30’

N/A

Table 2.1 PCR conditions for single amino-acd (AA) site-directed mutagenesis,
restriction endonuclease sub-cloning, and ligation independent cloning (LIC).
*Polymerase added once samples reached 95°C
Site directed mutagenesis was performed using two different protocols: For single amino
acid substitutions, fully overlapping primers (25-45 nucleotides) were designed using the
PrimerX webserver63 with Tm values optimized between 68-80°C; for inserts – restriction
sites and FLAGtag – primer design was performed as described in Liu et al. with primer
length not exceeding 45 nucleotides.64 (Table 2.1)
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Polymerase reactions were assayed by 1% agarose gel electrophoresis (80V x 45’,
constant potential) and incubated with 0.4 U/µl (typically 0.25µl in 10µ PCR reaction)
and incubated at 37°C 4-8 hrs. Digested pcr material was used for transformation
reactions.
Restriction Endonuclease Sub-cloning.
Generation of sub-clones of a given construct, i.e. N- or C- terminal truncations, were
performed by pcr amplification (Table 2.1) with primers harboring the desired restriction
endonuclease sequence constructed 5’AAATAATATTGT-Restriction_Site_ABCGene_sequence (5-7 codons, ending in G or C)—3’. PCR products (inserts) from these
primers were purified with ion-exchange spin columns (Quiagen) and digested in 30-40
µl reaction volumes containing 5-10 U of each restriction endonuclease (NEB) (as with
the desired vectors) for 8-16 hrs at 37°C. Digested vector and insert samples were
purified by1% agarose gel electrophoresis; desired DNA bands were excised, and
purified as above with ion-exchange spin columns. DNA concentrations were quantified
using Nanodrop spectrophotometry, and ligation reactions were performed using Quick
Ligase (NEB) following the manufactures protocol.
Ligation Independent Cloning.
PCR amplification of desired gene fragments was performed with forward and reverse
primers bearing LIC-compatible sequences at the 5’ ends. (Table 2.1) PCR products
were purified by 1% agarose gel electrophoresis as above and measured for concentration
by Nanodrop spectrophotometry. LIC-compatible vectors were digested with the
appropriate restriction endonuclease at 37° 8-12 hrs and similarly gel purified. Vector
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and insert samples were digested with T4 polymerase in the presence of only dGTP
(insert) or dCTP (vector) in 35 µl reactions: 30 µl gel purified vector or insert, 0.8 µl
100 mM dNTP (Fischer Scientific), 0.34 µl 100x BSA (NEB), 3.5µl 10x T4 Polymerase
buffer (NEB restriction endonuclease buffer #2), 1 µl T4 DNA polymerase (3000 U/ml,
NEB). The reaction was incubated at 24°C for 20’ and heat inactivated at 75°C for 30’.
Annealing of the digested insert and vector was performed by mixing 30-50 ng of vector
with a 5-fold molar excess of digested insert in a 10µl reaction volume (1x NEB
restriction endonuclease buffer #2). These reactions incubated 10’ at 42°C and allowed
to cool to room temperature for 10’, after which 1µl of 110 mM EDTA was added
(10mM final concentration). This annealed material (2-10 µl) was directly transformed
into chemically competent cells.
Competent cell production and transformation
Glycerol stocks of untransformed chemically competent cells were used to inoculate 1015 ml cultures and grown 12-16 hours at 37°C with 180-200 rpm rotary shaking in
Terrific Broth (Novagen) or Luria Broth (EMD) without antibiotic selection. Large
cultures (1-1.5 L) were started by inoculation with these overnight cultures and grown as
above to an OD600 between 0.2-0.3. Cells were harvested (3800g x 5’ at 4°C) and resuspended in 1/3 original culture volume with sterile 100 mM CaCl2 (pre-chilled on ice).
Cell suspensions were incubated on ice for 8-12 hrs, harvested as above, re-suspended in
1/100 original culture volume with sterile 100mM CaCl2 with 15% glycerol (pre-chilled
on ice), and snap frozen in LN2 in desired aliquots. Cells were stored at -80°C until use.
For cell lines harboring the pLysSRARE-CamR plasmid, the protocol above was modified
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to include the appropriate selection throughout the overnight and culture expansion
phases, but not the CaCl2 incubations.
Transformation of chemically competent cells:
Cells were thawed on ice, diluted four-fold with sterile, prechilled 100 mM CaCl2
(typically 20 µl cells: 60 µl CaCl2), and gently mixed with plasmid DNA: 0.2-1 µl
miniprep DNA, 2-4 µl site-directed mutagenesis reactions, 2-10 µl ligation/LIC annealing
reactions. Transformation reactions were incubated 30’ on ice, 2’ in 42°C water bath, 510’ on ice, and mixed with 350-400 µl sterile LB or TB without antibiotic selection and
incubated at 37°C with 220 rpm rotary shaking for 1-3 hrs before plating on LB agar
plates, pre-warmed and dried 30-60’. For all transformations of DNA from site-directed
mutagenesis, ligation-, and annealing reactions, DH5α cell lines were used. For protein
expression, BL21 DE3, BL21-AI, and BL21-Rosetta-pLysS strains were used. All
prepared as described above.
Alignments
Alignment of DNA and amino acid sequences were performed using PRALINE65,
CLUSTAL66, T-Coffee67, and BLAST.68
Limited Proteolysis
Samples of desired protein (2-8 mg/mL) were digested with empirically determined
concentrations of Subtilisin (usually 0.01-.1% protein:subtilisin) at room temperature and
on ice for 15-30 minutes (also an optimized variable). Digests were terminated by adding
SDS-PAGE loading dye and boiling the samples for 5 minutes. SDS-PAGE analysis of
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proteolysis was performed and transferred to PVFD membranes. Bands of interest were
assayed for N-terminal sequencing by the Rockefeller Proteomics Resource Center.
Ni-NTA Purification
All constructs of SopB, YpkA, and Gelsolin were purified similarly: desired constructs
were subcloned into modified Duet expression vectors (Novagen) containing a 3Cprotease cleavable 6xHis tag and grown under appropriate antibiotic selection in Terrific
Broth (Novagen) to an OD600 0.5-08 and induced with 0.05-0.1 mM IPTG and grown at
16-20°C for 36-38 hours. Cells were pelleted by centrifugation at 4°C, resuspended in
lysis buffer (4°C )with vigorous stirring (20-40 mM HEPES 7.4, 250 mM NaCl, and 10
mM imidazole) and flash frozen in liquid nitrogen. For purifications, cells were thawed
on ice and lysed by Emulsiflex (Avestin) 15-17,000 psi, 2 passes. Lysed material was
brought to 0.1 mg/mL DNAseI, 5 mM MgCl2, and 0.1 mM PMSF. Lysates were
incubated 30 minutes on ice and centrifuged. Cleared supernates were loaded 3x over
Ni-NTA matrix (typically 30 mL Ni-NTA for 6L worth of cell culture) with gravity flow,
washed with 10 column volumes of lysis buffer, 10 column volumes of wash buffer (lysis
buffer + 30 mM imidazole), and eluted with 4-5 column volumes elution buffer (lysis
buffer + 500 mM inidazole). Eluted fractions were analyzed on SDS-PAGE and desired
fractions pooled, assayed for protein concentration, and mixed 200:1 protein:His-tagged3C protease in dialysis tubing, which was dialyzed 16-48 hours with 2-3 changes agains
5L of gel-filtration buffer (20 mM HEPES pH 7.4, 200 mM NaCl, 1 mM DTT). Proteins
were then purified from the 3C-cleaved His tag by another pass over Ni-NTA and
purified further as desired using gel-filtration and ion exchange chromatography
following manufacturer’s protocols.
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Culturing Dictyostelium discoidium
A generic laboratory strain of D. discoidium was kindly provided by Larua Macro in the
lab of Sandy Simon at Rockefeller University. All stocks were grown axenically and
passaged in HL5 medium with glucose (referred to as HL-5g heretofore): HL-5
purchased as a dry mix from Formedium (ref# HLD0102) and prepared as per
manufacturer’s instructions supplemented with 20 mL 50% sterile glucose and 10 ml
Penn/Strep (10,000 Units/mL Penicillin and 10 mg/mL Streptomycin). The techniques
for culturing D. discoidium have changed very minimally from the original paper by
Ashworth and Watts in 1970, and much of the protocol followed for the below
experiments can be found therein.71 Frozen 1.0 mL stocks of D. discoidium were thawed
quickly by holding the tube in latex-gloved hands until the stock became slushy and
partly thawed whereupon the stock was pipetted into 10 mL of room temperature (2022°C) HL-5g in a sterile 100 mm plastic petri dish. Cells were allowed to adhere to the
bottom of the dish 4-8 hrs and the media was decanted and replaced with fresh HL-5g.
Cells were monitored for confluence and were split when the dish was 70-80% confluent
and cells were seen detaching from the surface. Splitting cells was performed by gentle
pipetting of the culture medium across the bottom of the plate to dislodge cells and then
adding 0.2-0.5 mL of the resulting cell suspension to a new plate and repeating as above.
When culture expansion in liquid phase was necessary, the cell density was determined
by manual hemocytometer cell counting methods and dilutions were made such that cell
densities were never below 1x104 cells/mL. Liquid cultures were grown at 19-20°C with
gentle shaking (100-140 rpm). Cells were harvested by centrifugation, washed in fresh
medium, centrifuged again and flash frozen as a pellet. For actin purifications from D.
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discoidium, cell pellets were thawed on ice and lysed in Emulsiflex (Avestin) on minimal
pressure settings (200-500 psi.). Lysate was analyzed by microscope to assess
completeness of cell lysis.
Culture of Acanthamoeba
Stocks of Acanthamoeba castellani were obtained from the lab of Dyche Mullins at
University California San Francisco and grown axenically as per his lab’s published
protocol.70 A second stock of Acanthamoeba castellani was purchased from the American
Type Culture Collection (ATCC). Empiric testing with the recommended culture
medium for the ATCC strain, the Mullin’s strain, and for the D. discoidium culture
discussed above, it was determined that Acanthamoeba grew as well if not better on the
HL-5g medium used for Dictyostelium. To simplify lab stocks, all cultures of
Acanthamoeba were grown in HL-5g in a manner very similar to that of Dictyostelium.
Maintained on plates, expanded in liquid, and grown in large batches when necessary.
Actin Purification
All attempts to purify actin strictly followed established protocol by Zuchero for
Acanthamoeba actin and Trasak et al. for Dictyostelium actin, personal communication.69,
70

Important elements of the Dictyostelium protocol are noted here as they are not

published, but it should be stressed that the expected results of the published protocols
were never reproduced. 10-30 Liters of Dictyostelium discoidium culture were harvested
with low speed centrifugation (1500 rpm/10 min), washed with 10 mM Tris pH 8.0 150
mM NaCl twice. Cells were resuspended in lysis buffer (2ml/g wet pellet; 30mM
Tris, pH8, 4 mM EGTA, 2mM DTT, 30% sucrose, 5 mM benzamidine, 2mM EDTA, 0.2
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mM ATP) and lysed in Emulsiflex (Avestin) ~ 500 psi, 1 pass). Lysate was cleared at
100,000xg for 90 min, pellet washed with lysis buffer, same spin, keeping the cleared
lysate, which was adjusted pH to 8.0 and loaded onto equilibrated DE52 (2/3 of the resin
in the column (3cm x 50 cm), 1/3 of the resin stirred into the homogenate for 30 min,
slurry then loaded onto the fresh DE52 in the column); the reason for this
procedure: if one has large amounts of homogenate the loading takes a long
time and actomyosin has time to flocculate, to build a considerable layer
of fluffy material on top of the resin, and clogg the tubing. A batch procedure was an
attempt to avoid this difficulty. After the slurry (dark yellow) is
nicely packed, the column is washed with at least two column volumes of
10mM Tris, pH 8.0, 1mM EGTA, 1mM DTT, 0.02% NaN3, 1mM benzamidine, 0.5 mM
PMSF, 0.1 mM ATP (called 'TEDABPA' also column equilibration buffer). Elution of
bound proteins was performed with a 0-400mM linear NaCl gradient over 10 column
volumes. This step was quite difficult as the column would routinely clog and require
very slow flow rates (0.1 ml/min), which equated to days of running the column. Actin
elutes at about 120-175 mM NaCl. The column profile was checked by SDS PAGE and
actin fractions pooled. After a 0-35% ammoniumsulfate precipitation the pellet is well
dialyzed (48 hrs with frequent changes at 4°C) against normal G-buffer. The dialysate
was ultracentrifuged (100,000 g x 60 min), pellet discarded, and supernatant treated with
2 mM MgCl2, 50mM KCl, 1mM ATP, 2 h, at 4°C. After this step of actin
polymerization, the sample was ultracentrifuged at 100,000g for 3h. The glassy pellet
was homogenized with a glass homogenizer, and dialyzed thoroughly against G-buffer
for depolymerization. Another ultracentrifugation spin was performed to clear
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polymerized actin (100,000g x 3h at 4°C). Only the upper 2/3 of the supernatant in the
centrifugation tubes were recovered from final ultracentrifugation step to try and obtain
actin monomers and avoid multimers that aren’t sufficiently large to pellet upon
centrifugation.
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Chapter 3: Protein Purification and Initial Crystallization
** The work presented below that preceeded initial x-ray data collection was performed
by Pete Stavropoulos prior to- and independent of- the author’s involvement with this
project.
Initial attempts to recombinantly express tbADAT2 (wt) were hampered by low yields
and high molecular weight species likely resulting from cysteine cross-linking. Sitedirected mutagenesis of individual cystine residues identified C117S, (heretofore called
tbADAT2 as opposed to tbADAT2 (wt), as a key mutation that greatly increased
expression, solubility, and stability. tbADAT2 was subsequently expressed with a 3Cprotease cleaveable N-terminal 6xHistidine tag via a protocol involving an initial NiNTA purification followed by 3C digestion, Heparin-Agarose ion-exchange, and two
rounds of gel filtration (Fig. 3.1 A-D). Purified tbADAT2 was well-behaved, soluble,
and non-aggregating, even at concentrations in excess of 100 mg/ml.
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Figure 3.1. Purification steps of tbADAT2 shown as FPLC elution profiles (uv trace in
blue, gradient in yellow) and SDS-PAGE analysis of peak fractions, left and right panels,
respectively. A. Ni-NTA elution (20-500 mM Imidazole) B. Hi-Trap Heparin-agarose
(50-500 mM NaCl) C. Superdex 200 (Elution Peak ~78.0 mL) D. Superdex 75 (Elution
Peak 52.0 mL)
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Crystallization screens of tbADAT2 at 100-105 mg/ml yielded a positive crystallization
condition at 4°C that was optimized within the following range of conditions: 880-1120
mM Na/K tartrate, 200 mM LiSO4, and 100 mM HEPES pH 6.5-7.2. Crystals were
elongated square dipyrimids (~0.3 x 0.1 mm) with rounded edges such that they appeared
more like an ellipse and lacked a sharp, facetted appearance. (Fig. 3.2)

Figure 3.2 tbADAT2 crystals grown 14 days at 4°C by vapor diffusion over 944 mM
Na/K Tartrate, 200 mM LiSO4, 10 mM HEPES pH 6.9.

The largest crystals are

approximately 0.3 mm in the longest dimension.
Initial tbADAT2 crystals were cryoprotected in 20% glycerol and complete datasets were
collected on several samples. The best of these datasets was successfully indexed,
integrated, and scaled in space group p41212 with unit cell dimensions
62.74x62.74x228.80, 90,90,90 (see table 1); however, the data had a mosaicity ranging
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from 1.1-1.8 (also evidenced by the “smeary” appearance of the diffraction data) and
showed strong anisotropic diffraction with resolution limits of 3.6x3.6x3.2 Å 48. (Fig. 3.3)

Figure 3.3. Diffraction data for tbADAT2 crystals in 20% glycerol showing roughly one
quadrant of the detector field. The resolution of diffraction at the decector edge is ~2.9Å.
The best diffraction on this image is ~3.1 and ~3.7Å in the vertical and horizontal axes,
respectively.
The Matthew’s coefficient for these data suggested an asymmetric unit comprising 2
monomers with a solvent content of 48.5%. Using these parameters and a homologous
monomer from the hsADAT2 structure32 as a search model (36% identity), a molecular
replacement solution was obtained from these data with an R-work/R-Free of (35.0/42.0)
for an auto-built structure comprising 324 of the total 450 amino acids in the dimer.
Maps of this structure revealed general fold information, including interpretable regions
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of β-sheet and α-helix, and the density for the coordinated zinc was clear; however, sidechain detail for key residues in this region was minimal if not absent. (Fig. 3.4) In total
46% of residues in this model were categorized as having acceptable density while the
remaining residues were categorized as having weak to very weak density by the
autobuild module of PHENIX.
Attempts at de novo structure determination with Zn-MAD/SAD and with Se-methionine
derrivatized tbADAT2 crystals were unsuccessful. Fluorescence scans of the crystals
around the Zn-peak for the purpose of anomolous phasing failed to detect a useable
signal, and data quality Se-methionine tbADAT2 crystals were not obtained.

Figure 3.4. View of the Zn-binding motif in the auto-built model of the molecular
replacement solution of tbADAT2 with density modified maps contoured at 1.0 sigma
(blue) and 5 sigma (red) showing the overall lack of detail in this solution.
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Chapter 4 Crystal Optimization, Data Collection, and Processing
Crystallization trials were repeated as above at 4°C using a more detailed grid of Na/K
Tartrate concentration (880-960 mM) in 8 mM steps with 200 mM LiSO4 and 100 mM
HEPES pH 6.6-6.9 (0.1pH unit steps). Data quality crystals were harvested from all
conditions of this grid, with optimal conditions lying between 930-960 mM N/K tartrate
and pH 6.8. Below and above these points growth decreased and nucleation increased,
respectively. Using these crystals, several cryoprotection strategies were attempted to
improve the diffraction data quality. Solutions containing 2-3 M Na acetate and Na
malate were tried both alone and in combination with each other in an attempt to find a
suitable cryoprotectant.72 These solutions vitrified well and had very low background
diffraction, but no transfer method into these solutions was found for the tbADAT2
crystals that did not deleteriously affect diffraction. An alternative approach to stabilize
the crystals before cryoprotection through glutaraldehyde cross-linking73 also failed to
improve upon the diffraction described in Chapter 3. It was noted during cryoprotection
trials that using the crystallization well solution as a cryoprotectant did preserve
diffraction as well as- or better than- that observed previously, but significant ice-ring
diffraction remained problematic. Na/K tartrate can serve as a cryoprotectant at
concentrations near 2.0 M, which is very close to its saturation point.72 Such
concentrations were unattainable when considering the dilution factor resulting from the
addition of the other reagents in the well solution and the necessity to chill all buffers to
4°C. A dehydration protocol was developed using vapor diffusion wherein the well
solution with saturated Na/K tartrate served as a dehydrant followed by an evaporation
step of the crystal-containing drop, which drove the Na/K tartrate to saturation. Crystals
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were cryo-cooled in L2N directly from the evaporating drops. Dehydrated tbADAT2
crystals showed improved resolution and decreased mosaicity.
Diffraction data for these dehydrated crystals showed diffraction resolution in-house that
was nearly equivalent to the resolution glycerol treated crystals had shown using a
synchrotron x-ray source. Additionally, these data showed decreased anisotropy and
decreased mosaicity. (Fig. 4.1A)

Figure 4.1. Diffraction data on the identical crystal of tbADAT2 croyo-protected in
saturated Na/K tartrate following dehydration: A. 15 minute exposure using in-house
rotating Cu-anode x-ray source with diffraction to 3.2Å. B. 1.0 second exposure on
beamline X29 at National Synchrotron Light Source with diffraction to 2.8. Asterisk (*)
indicates visually appreciable diffraction limit.
Data collection on the same crystal using in-house and then synchrotron x-ray sources
showed a significant increase in resolution from 3.2 to 2.8Å, respectively. (Fig. 4.1)
Using a robotic auto-mounter, 34 crystals were screened on the synchrotron x-ray source.
These crystals exhibited a range of data quality (sharp to moderately mosaic) and
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resolution (2.4-3.1 Å). The four best crystals were selected for full dataset collection.
Two native datasets were collected at a wavelength of 1.0750 Å (the optimal wavelength
for beamline X29). Following a fluorescence scan of a test crystal that showed a small
but measurable zinc signal (Fig 4.2A), two full datasets were collected at the empirical
Zn-peak of 1.2826 Å for use in SAD phase determination, which is in close agreement to
the theoretical Zinc edge. (Fig 4.2B B) It is important to note that Zn was never added to
buffers during purification nor during crystallization, suggesting a very tight association
with the structure and consequently a high occupancy in the crystal lattice.

Figure 4.2 X-ray fluorescence spectra of tbADAT2 showing A. the empirical Zn-edge
determination for SAD/MAD data collection compared to B. the theoretical Zn-edge.
The mosaicity for these data was between 0.48 and 0.98, which, when combined with the
long unit cell (228.6Å) required modification to the typical spot-finding and integration
parameters to accurately measure individual reflections against background. The
orientation of the long axis of diffraction (i.e. the dimension with the tightest spacing)
was oriented such that a rectangular spot-finding profile allowed for an increased area of
background measurement while avoiding overlapping data. (Fig. 4.3)
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Figure 4.3

Integration profiles used for data processing.

A. showing overlapping

profiles that were remedied by a the rectangular profile in B. A schematic of the three
regions comprising the generic spot profile is shown in C: background (blue), disregarded
buffer (red), and integrated diffraction spot (green).
Diffraction data were scaled to 2.95Å (I/σI = 2.44) and the final space group of
P4(1)2(1)2 was determined empirically by inspection of systematic absences during
scaling as well as by comparison to the results of the molecular replacement solution
discussed above. Individual scale error factors were then adjusted to optimize overall χ2
to 1.0. At this point a clear, resolution dependent deviation of χ2 for merged vs. unmerged Friedel pairs were seen above ~3.9Å indicating the presence of an anomalous
signal for the Zn-SAD dataset. (Fig 4.4A) Data analysis with the X-triage module of
PHENIX confirmed the presence of a measureable anomalous signal (Fig. 4.4B) while
also ruling out the presence of twinning and other crystallographic features that can
complicate structure determination (not shown).
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Figure 4.4 Measurable anomalous signal from tbADAT2 crystal diffraction collected at
the Zn-peak as assessed during scaling (A) and initial phasing (B) by HKL2000 and
PHENIX, respectively.
Native high-resolution tbADAT2 diffraction data were scaled using several different
approaches to generate data to be used to extend the resolution of the de novo phase
solution from the Zn-SAD data. Briefly, these data were scaled with and without regard
for the potential anomalous signal of this data and each of these datasets were then
truncated for either isotropic or anisotropic diffraction.
Initial data processing was performed as above to address the issue of elevated mosaicity
with a long unit cell, and the data was additionally scaled with or without the presence of
an anomalous signal given the wavelength of data collection was still within the region of
the x-ray spectrum that interacts with Zn atoms. (Fig. 4.4B) Both the anomalously and
non-anomalously scaled native data were truncated for isotropic/spherical diffraction at
2.56 Å (I/σI = 2.58), or the data were first truncated at 2.5Å (I/σI = 1.0) and subsequently
truncated anisotropically/elliptically to a resolution of 2.8x2.8.2.5Å.
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Table 4.1: Crystallographic statistics

Data Collection

Space Group

tbADAT2 native

tbADAT2 native
anomalous and anisotropic

tbADAT2 (Zn-peak)

tbADAT2 -20%gly.

P4(1)2(1)2

P4(1) 2(1) 2

P4(1) 2(1) 2

P4(1) 2(1) 2

a, b, c (Å)

62.49, 62.49, 228.37

62.49, 62.49, 228.368

62.437, 62.437, 228.637

62.747, 62.747, 228.843

α, β, γ (°)

90, 90, 90

90, 90, 90

90, 90, 90

90, 90, 90

Resolution (Å)

50-2.5 (2.54-2.5)

50-2.69 (2.6-2.5)

50-2.95 (3.0-2.95)

50.0-3.16 (3.21-3.16)

Rsym (%)

10.5

10.5

11.6

12.1

Anisotropy*

2.8x2.8x2.5

N/A

N/A

3.6x3.6x3.2

Mosaicity

0.492-1.096

0.492-1.096

0.485-0.981

0.649-1.749

I/σI

27.754

27.919 (2.58)

32.375 (2.44)

38.625 (2.2)

Completeness (%)

NA

99.9 (39.3)

98.5 (49)

99.2 (35)

Completeness Anisotropic (%)

80.74 (7.44)

N/A

N/A

N/A

Redundancy (anomalous)

14.2 (10.5)

26.7

13.5 (11.2)

47.3 (33.7)

Refinement
Resolution (Å)

N/A

41.22-2.56

44.1-2.95

48.46-3.16

Resolution anisotropic (Å)

41.22-2.8x2.8x2.5

N/A

N/A

N/A

No. reflections

11992

415,761

243626

410,013

11992

8617

8172

0.2579 / 0.2958

0.2941 / 0.3582

0.2854 / 0.3609

0.3534 / 0.4189**

Protein

2375 (313 Cα)

2375 (329 Cα)

2224 (327 Cα)

2270 (324 Cα)

Water

0

0

0

0

Zinc

2

2

2

0

Overall Score

96th percentile

17th percentile

4th percentile

0th percentile

Clash score all atoms

96th percentile

85th percentile

13th percentile

3rd percentile

1.23

17.0

22.53

44.39

Most favored (%)

94.31

68.89

66.03

55.12

Allowed (%)

5.69

86.35

18.73

35.98

Outliers (%)

0

13.65

15.24

19.14

Bond lengths (Å)

0.0177

0.015

0.013

0.017

Bond angles (°)

1.646

1.923

1.73

2.266

Cell Dimensions

Unique Reflections
Rwork / Rfree
No. Atoms

Poor rotamers (%)
Ramachandron plot

R.m.s deviations

* Anisotropically truncated data were initially scaled to 2.5 Å so as not to eliminate
useful data. These data were then subsequently analyzed for anisotropic diffraction and
truncated elliptically as described above.
**Rwork/Rfree for this models is for the unrefined autobuilt model with no manual
model building/correction.
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Chapter 5 Structure Determination
Phases were determined for the Zn-SAD dataset using Auto-Sol in PHENIX. An initial
calculation of the measurability of the Zn-anomalous signal was 0.0637 and extended to
4.0Å (acceptable >0.05). For this data, two phase solutions were found with p4(1)2(1)2
receiving the highest scores for electron density skew (0.08), figure of merit (0.29) and
estimated map correlation coefficient (40.6 +/- 29.0). Acceptable values for skew and
figure of merit are 0.10 and 0.3, respectively, so the values for the Zn-anomalous solution
were slightly less than acceptable levels. Solvent flattening performed with RESOLVE
in PHENIX yielded initial electron density maps with clear protein/solvent boundaries
(Fig. 5.1A-B), which, when contoured at 5σ (Fig 5.1C), showed very clear density for the
individual Zinc atoms with a pattern of eight pairs of zinc atoms per unit cell
corresponding to eight dimers (one dimer/asymmetric unit).

Figure 5.1. Electron density from initial phase solution of tbADAT2 (A) and the same
density following solvent flattening with RESOLVE contoured at 1σ (B) and at 5σ (C).
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Automated model building was attempted using both ARPWARP and AutoBuild
(PHENIX), with only the latter achieving successful results. The resulting model
comprised 223 residues in 3 chains with an Rwork/Rfree of 0.3546 / 0.4042 (Fig. 5.2A).
Alignment of hsADAT2 to this initial model (RMS 3.69Å for 169 residues) revealed
general information about the initial structure allowing assignments to be made for the
various fragments with regard to monomer and residue numbering. (Fig 5.2B)

Figure 5.2 Resulting tbADAT2 structure from automated model building (A) aligned
with hsADAT2 in beige (B).

In A the three colors represent three different chain

assignments made by the autobuild software that can be seen to align to one of two chains
in the hsADAT2 structure.
Manual model building initially focused on one of the two monomers, which was built
using the initial F0-Fc density map contoured at 1σ. Of the 225 residues in the monomer,
157 were built into clear, continuous electron density. The model of the initial monomer
(A) was then aligned to the opposing monomer (B) and used as a template to finish
building the dimer. At this point, the correct dimer interface was distinguished from
crystal contacts using PISA in addition to alignments with- and comparisons to-
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published protein structures containing the cytidine deaminase fold.74, 75 Refinement of
the completed model against the Zn-SAD data to 2.95Å resulted in an Rwork/Rfree of
0.30/0.34.
The refined tbADAT2 model was improved through additional rounds of model building
and refinement against the higher resolution native data. In all cases the freeR data from
the initial solution were appended to the higher-resolution native data to ensure
meaningful Rfree calculations. Initial refinement against these native data truncated
isotropically at 2.56Å (I/σI = 2.58) without anomalous scaling showed marginal
improvement of the model during refinement and resulted in electron density maps with
little increase in detail. Anomalous refinement of the tbADAT2 model against native
data scaled anomalously at 2.69Å (I/σI = 2.48) showed improved Rfree values that were
lower still when refinement accounted for non-crystallographic symmetry or when the
pre-refined model was subjected to TLS analysis. Additionally, the Rfree was improved
by refinement against anisotropically truncated data (2.8x2.8x2.5Å) that included the
strongest higher resolution diffraction while simultaneously discarding the noisy, weak
diffraction in the higher resolution data shells. The improvement on Rfree was found to
be relatively independent and additive for these three approaches, so the best refinement
strategy was found to be restrained anomalous refinement on anomalously-scaled,
anisotropically truncated native data in combination with a model subjected to TLS
analysis prior to rounds of refinement. Throughout model building and refinement,
geometric restraints and Ramachandran statistics were monitored within COOT and using
MOLPROBITY to assess and remedy problematic regions of the model. This approach
yieled a final tbADAT2 with an Rfree/Rwork of 29.6/25.8 and a MOLPROBITY scores for
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all-atom contacts and protein geometry in the 96th percentile out of 6730 structures with a
resolution of 2.51 +/- 0.25Å. The final model had no Ramachandran outliers and had
94.3% of residues in favored regions. (Fig 5.3)

Figure 5.3. Ramachandran plot generated by MOLPROBITY of final tbADAT2 model
showing, clockwise from upper left, all residues, glycines, pre-prolines, and prolines:
94.3% of all residues in favored regions (light blue), 100% of residues in allowed
regions.
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The improved refinement with higher resolution data failed to clarify regions of
discontinuous electron density in the initial model: residues 1-18, 108-121, 161-184, and
209-225. (Fig. 5.4 A-B) Several attempts were made to improve the electron density
maps in these areas including simulated annealing and the calculation of composite
omission maps. Several automated loop-building applications in PHENIX and
ARPWARP were also used to improve the model of these unresolved areas of density.
Neither of these additional approaches yielded any improvement.

Figure 5.4. Discontinuities in final model of tbADAT2 model and refined 2Fo-Fc
electron density map contoured at 1.0σ showing the two regions of discontinuity in the
structure: A S108-S121 and B G161-I184.
Finally, attempts were made to add the Zn-coordinated water molecule that has been seen
in homologous structures at higher resoltuion. While the density wasn’t perfectly clear
for the placement of water, it did appear that density surrounding the zinc ion exhibited a
bulge in the correct direction to indicate the presence of this water. (Fig. 5.5) Multiple
refinement attempts following the addition of this water molecule to the model failed to
satisfactorily refine the location of the water, so this water molecule was not included in
the final model.
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Figure 5.5. Final tbADAT2 model and refined 2Fo-Fc electron density contoured at 2σ
showing the active-site zinc and surrounding zin-coordinating residues.

A water

molecule is shown modeled (not refined) into the bulge in electron density surrounding
the Zinc with distances to the Zn and E92 of 1.61 and 3.65Å, respectively.

!

47

Chapter 6 Structure Analysis
The structure of tbADAT2 was solved to 2.8x2.8x2.5Å resolution in space group
p4(1)2(1)2 by SAD phasing off one natively bound zinc atom per monomer,
demonstrating a phasing effectiveness of one anomalous scatterer for 225 amino acid
residues. The structure contains clear density for 313 of the 450 residues (69.6%) in the
asymmetric unit, which comprises a dimer formed across an extensive, primarily
hydrophobic interface burying 2285 Å2 between two monomers related by noncrystallographic two-fold rotational symmetry. (Fig 6.1 A) Two additional interfaces are
seen in the crystal which burry 892.8 and 689.8 Å2, both of which have been classified as
crystal packing interactions based on comparisons to homologous structures and
structural analysis with PISA (Protein Interfaces Surfaces and Assemblies).76
The structure of tbADAT2 exhibits a topology closely resembling other members of the
cytidine deaminase family to which it belongs. Each monomer contains a single domain
with the canonical cytidine deaminase fold comprising a mixed 5-strand β-sheet core
sandwiched on one side with two long α-helices forming the outer border of the
monomer and on the other side with a set of three α-helices that form both the Znbinding cleft and the dimer interface. (Fig. 6.1A) Each monomer contains a single
coordinated zinc ion with apparent tetrahedral coordination geometry consistent with
other members of the cytidine deaminase family. Three residues coordinate the zinc,
His90 (1.83Å), Cys136 (2.39Å) and Cys139 (2.18Å). A fourth coordination is believed
to be provided by an activated water as in many zinc metallo-enzymes. Evidence of this
water is suggested by the electron density around the zinc (Fig 5.5); however the
presence of a coordinating water is not certain as various attempts to refine this water
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proved inconclusive. The B-factors for the final structure follow the degree of
conservation of the cytidine deaminase fold with the most conserved core region
exhibiting B-factors in the 20s-30s smoothly transition up the the mid 50s-60s for
boundary regions of the protein that are less highly conserved. Residues 54-76 form an
unstructured, non-conserved loop that exhibit the highest B-factors of the structure
indicating a high degree of flexibility. This loop was particularly difficult to refine
successfully and contains some of the weakest density in the structure. The B-factors for
the middle of the loop (125) are at the same level of residues immediately preceding and
following other breaks in the electron density (see below). Therefore, while the loop did
refine successfully as built, any serious structural conclusions made regarding its
structure and orientation must be made with the above discussion in mind.
Other structural features of the monomer are eight distinct intra-chain salt bridges that
serve to tie the outer and inner bundles of α-helices together as well as to tie the helices
to the β-sheet core. No disulfide bonds are seen between any of the six cysteines that are
not involved in coordinating the zinc.
Structural alignments of tbADAT2 with other ADAT homologues reveal a high degree of
conservation of the cytidine deaminase fold. (Fig. 6.2D) Sequence identities for these
alignments were 32, 34, and 42% with r.m.s. deviations of 1.3, 1.5, and 1.9Å. for
atADAT, saADAT, and hsADAT2 homologues, respectively. (Fig. 6.2B) This high
degree of conservation is exemplified at the active site zinc where the structural
conservation of the HAE…PCIMC domain is quite high with the coordination geometry
remaining nearly identical for all 4 examples compared. (Fig. 6.1C) Several of the
homologues contain coordinated water, and the location matched the orientation of the
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indicative bulge in electron density discussed above for the zinc-coordinated water the
tbADAT2 structure.
The dimer interfaces for the hsADAT2, saADAT, and atADAT structures were all within
100Å2 of the tbADAT2 structure and were all equally hydrophobic. While alignments of
individual monomers from these homologues show the high structural homology
mentioned above, a fair degree of structural diversity is seen across the dimer interface
with monomers rotated 20-30° across the dimer interface relative to the tbADAT2
structure. This rotation is seen between structures both with and without substrate bound,
so it does not appear to be a substrate-related conformation switch, although the
differences certainly alters the substrate binding cleft, as discussed below.
A sequence alignment of tbADAT2 with hsADAT2, saADAT, and atADAT identified
three regions in the tbADAT2 sequence that contained insertions and/or regions of low
homology vis-à-vis other members of this family, referred to here as loops A (residues
54-71), B (105-120), and C (172-190). (Fig 6.2 A) Of these, only loop A is seen in the
tbADAT2 structure and protrudes away from the bulk of the core fold at the base of the
β-sheet, opposite the opening to the active site of the monomer to which it belongs. It is
loop A that was referenced above for exhibiting high B-factors suggesting this loop is
likely more mobile than the surrounding structure. (Fig. 6.2 B-C) The loop itself was
initially built as a small helix turn helix sub-domain, but attempts to model the loop as
such yielded consistently poorer results than the final orientation of the loop modeled
without α-helical restraints, as shown here. (Fig. 6.2C)
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Figure 6.1. Structure of tbADAT2 showing (A) the dimer comprising the asymmetric
unit with a space-filling representation of the dimer interface colored for electrostatic
potential.

(B-D) Structural alignment of tbADAT2 with homologous structures

hsADAT2 (pdb3DH1 in red), S. aureus TadA (pdb2B3J in cyan B, and A. tumefaciens
(pdb2A8N in coral). The alignments in (B) were performed using rigid models such that
the high structural homology can be observed for the monomers (right side in B, in C and
D) and the disordered alignment on the left in B shows the degree of structural variability
of the dimer. Active site labels in C correspond to tbADAT2. Gray and red spheres are
zinc and water, respectively.

Alignments in D depict sequence and topology

conservation between these homologues structures for ordered regions only. Stereo view
available in appendix I.
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Figure 6.2 Sequence and structural analysis of non-homologous insertions in tbADAT2
amino acid sequence relative to homologous ADATs (A) Sequence alignment colored by
conservation from lowest (blue) to highest (red). (B) Two views rotated by 180° about
an axis in the plane of the paper (arrow) of the final tbADAT2 homodimer depicted as a
ribbon diagram showing the location of the insertions identified in panel A. Loop A is
seen near the axis of rotation. Loops B and C are not structured and are indicated by
general location with green arrows. (C) Structures as in B showing a view from the top of
the dimer looking into the binding site of blue monomer. Loop A is depicted as a space
filling model colored for electrostatic potential. “Loop B” is indicated as such.
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Given the rotational symmetry of the dimer, loop A of one monomer is on the same face
as the opening to the active site of the other monomer of the dimer. (Fig. 6.2 C and 6.3)
A space filling model for loop A colored for electrostatic potential shows a relatively flat
surface with regions of positive and negative potential that forms part of an extended face
oriented toward the direction that substrates would approach the active site of ADAT2.
Loop B of monomer A also forms a portion of this face and is positioned to form and or
extend the substrate-binding surface adjacent to the active site; however, given the lack of
density for this region, the orientation can only be inferred from the location and
trajectory of the structured at the beginning and end of this loop. (Fig. 6.3) The same can
be said regarding loop C, which covers the one side face the structure (if the substrate
binding clefts are referred to as the top and bottom). The beginning and end of this loop
suggests that loop C covers most of the side of the structure and likely interacts with loop
C from the other monomer in the dimer. The function of these insertions can only by
hypothesized at this point; however an interesting possibility will be discussed below that
these insertions enable a significant domain swap upon hertero-dimerization with
ADAT3. BLAST analysis shows that the A, B and C insertions are present in ADAT2
form other trypanosomes and possibly some leishmania species but are noticeably absent
from ADATs from higher eukaryotes and prokaryotes.
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Figure 6.3 Space filling model of tbADAT2 showing Loops A and B in relation to the
active site. Monomers are in magenta and blue. Loops are colored for electrostatic
potential, as is the catalytic core of the blue monomer.
The active site: The binding of an RNAstem loop substrate has been characterized
crystallographically for the prokaryotic saADAT which was shown to bind two RNA
substrates per dimer, one each at two solvent exposed clefts on opposite sides of the
dimer formed at the interface between the two monomers.27 (Fig. 6.4A) The interactions
between the dimer and each RNA stem loop were extensive with a total of 17 residues
contacting each substrate. (Fig. 6.4B) At each binding site, the majority of the residues
contacting the substrate arise from the same monomer containing the active site zinc
associated with the respective active site, however, several significant contacts are made
by residues of the adjacent monomer. A sequence alignment was used to identify the
corresponding residues in tbADAT2. Of these 17 residues, 6 are identical between the
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two structures. The remaining 11 equivalent positions in tbADAT2 show a few
conservative mutations, but a significant portion have non-conservative mutations that
appear on a structural alignment to alter or eliminate altogether the interaction those
residues would make to the aligned RNA substrate. (Fig. 6.2B, Table 6.1) A model made
by docking a tRNA structure onto the stem-loop of the saADAT structure does not
indicate any additional regions of contact between the tRNA and the ADAT molecule.
(Figure 6.3)
asADAT
A
G22
I26
N42
R44
H53
A54
E81
D103
D104
K106
S138
R149

tbADAT2

B
R70
E72
R94
N123
R125

A
G42
V46
N79
T81
H90
A91
E134
T156
N157
R159
V198
N209

B
D123
A125
R147
L180
G185

Table 6-1 Residues involved in RNA binding in saADAT vs. tbADAT2 based on
sequence alignment. Bold residues are conserved.
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Figure 6.4 Modified stem-loop bound to saADAT. A) Showing the dimer and bound
stem loop side chains for residues that contact the RNA. Grey is monomer A with blue
side-chains, Orange is monomer B with green side-chains. Pink and magenta show bound
stem-loop molecules with the substrate analogue zebularine represented as spheres. B)
Zoomed view of RNA-ADAT interaction. Colors as in A with tbADAT side-chains from
equivalent monomers A and B in magenta and cyan. C) Equivalent view as in A with full
length tRNAile

77

manually aligned to the stem-loop structure. Stereo view available in

appendix I.
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Modeling of the ADAT2/3 homodimer
Spears et al. have generated two models of the hsADAT2/tbADAT3 homodimer with and
without a proposed domain swap that involves the C-terminal 100 residues of ADAT2 in
a symmetrical swap with an eqivalent C-terminal domain of ADAT3 38. This model was
initially based on the hsADAT2 crystal structure and a computational model of
tbADAT3. To generate a more suitable model of the tbADAT2/ADAT3 heterodimer, the
models from Spears et al. were modified to replace the hsADAT2 portions with the
tbADAT2 structure from the present study. No computational models were uses to make
this substitution. When compared to the tbADAT2 structure, the two monomers of the
hsADAT2 are rotated approximately 20° counterclockwise about an axis almost
perpendicular to the dimer interface; consequently, the starting heterodimer model
reflected this orientation. A new model was created by re-aligning the tbADAT3 portion
of the original model with monomer B of the ADAT2 homodimer. This new orientation
was then copied into a new model with ADAT2 monomer A to form the heterodimer.
With the unswapped model of tbADAT2/3 as guide, the domain swap portions of each
monomer were realigned to generate a representative domain swap model with the
appropriate ADAT2 and ADAT3 amino acid sequence and residue numbering. (Fig. 6.5
A-D) The final domain swapped model comprises the native postions of residues 1-108
of ADAT2 and 1-272 of ADAT3 and swapped positions for residues 121-209 of ADAT2
and residues 276-365 of ADAT3. The cross-over of the domain-swapped region of
ADAT2 corresponds with loop B discussed above, for which there is no density in the
tbADAT2 homodimer model. For this reason, the actual cross-over loops between the
native and swapped orientations of ADAT2 and ADAT3 were not modeled. This model
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was used for structural comparisons and for the design of disulfide cross-linking
experiments.

Figure 6.5 Purported domain swap models of tbADAT2/3 showing tbADAT2 (pink) and
tbADAT3 (blue) as both cartoon and ribbon diagram depictions of the un-swapped
dimers (A and C) and the domain swapped dimers (B and D). Proposed disulfide crosslinks are shown in yellow (B and D). Stereo views available in Appendix I.
An analysis of the swapped and un-swapped tbADAT2/3 heterodimer models was
conducted using the Disulphide by Design® web-server 61, which identified numerous
sites amenable to favorable disulfide formation. These results were analyzed in the
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context of the starting models to identify bond pairs that when cross-linked would yield a
clear characteristic banding patterns on SDS-PAGE depending on the swapped state of
the dimer. Candidate pairs were rejected if they were too close to the active site
cysteines. This resulted in a total of eight pairs of mutations. (Table 6.1, Fig 6.6) Three
additional cystein pairs were identified to generate several positive controls for this
experiment. These included an intra-chain pair in ADAT2 (Cys34-Cys78), an inter-chain
disulfide in the ADAT2 homodimer (Cys141), and an inter-chain disulfide in the
ADAT2/3 heterodimer that would be the same in the either the swapped or non-swapped
configurations (ADAT2 Cys141 – ADAT3 Cys 296) (Fig 6.6)
Table 6-2 Disulfide cross-linking mutagenesis
Pair #

Residue #1

Residue #2

1

ADAT2 P45C

ADAT3 H354C

Disulfide if domain swapped

2

ADAT2 Cys48*

ADAT3 V268C

B-Yes

B- No

3

ADAT2 L200C

ADAT3 G201C

A’ – Yes

A’ – No

4

ADAT2 V131C

ADAT3 A204C

B’ – Yes

B’ – No

5

ADAT2 Y130C

ADAT3 F183C

C – Yes

N/A

6

ADAT2 P45C

ADAT2 L200C

A – No

A – Yes

7

ADAT2 Cys48

ADAT2 V131C

B – No

B—Yes

8

ADAT3 G201C

ADAT3H354C

A – No

A’ – Yes

A-yes

Disulfide if no domain swap
A-no

* Cysteine residues native to the sequence
These mutations were created by site directed mutagenesis of a his-tagged tbADAT3
construct in pet28Kan and an untagged tbADAT2 construct in position two of pETDUETAmp. Co-transformations of these two pET vectors was very inefficient, frequently
with only one or two double-resistant colonies per reaction compared to >100 for the
same conditions with a single selection for one construct. The doubly transformed strains
were successfully grown and induced, and the his-tagged ADAT2 and ADAT3 were
purified in a manner similar to the method described above for ADAT2 with the major
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difference being absence of reducing conditions to preserve disulfide formation;
however, significant background, low yield, and considerable laddering complicated
attempts at purification. It seems likely these difficulties were encountered due to the
absence of reducing agent. Screening for optimal induction cell lines and induction
condition identified the strongest induction in BL21-AI cells induced at 37°C for 2-3
hours with 0.5 mM IPTG and 0.1% arabinose; however purification attempts on material
from these cells showed highly insoluble material that was not recoverable through either
batch dialysis refolding nor on-column refolding. These experiments are ongoing with
the focus on optimization of induction and of purification to identify the minimal
concentration of reducing agent necessary to facilitate purification without compromising
specific disulfide formation. Several additional options are available to pursue, including
the creation of a minimal cysteine background sequence for both ADAT2 and ADAT3.
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Figure 6.6.

Schematics of disulfide cross-linking interrogation of ADAT2/3

heterodimer.

Panels A-C depict predicted disulfide formation between introduced

cysteine residues: A as a control in the ADAT2 homodimer, B in the domain swapped
ADAT2/3 heterodimer, and C in the non-domain swapped ADAT2/3 heterodimer.
Panels D-E depict predicted migration of purified material run on SDS PAGE in reducing
(R) or oxidizing (O) conditions. Panels D, E, and F correspond to the schematics and
disulfide pairs in A, B, and C, respectively, showing decreased migration due to interchain disulfide formation and increased migration due to intra-chain disulfide formation.
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Chapter 7 Discussion
Comparisons between prokaryotic and eukaryotic tRNA editing of A34 in the anticodon
wobble position highlight several distinct gaps in our understanding of how the
eukaryotic enzymes function. Moving from prokarya to eukarya, the enzymes that
deaminate A34 in tRNA exhibit a more permissive substrate specificity, a requirement
for ADAT2/3 hetero-dimerization instead of ADAT2 homo-dimerization, and show a
more diverse spectrum of enzymatic activity. Cells have evolved the ability and need to
dynamically modify the genetic information they carry, and in many cases, including
those performed by the ADAT family of enzymes, these modifications are essential.
Understanding the regulation of these enzymes is an important step toward understanding
the rules that govern RNA editing in higher eukarya and will likely pertain to a wider
field of epigenetic gene regulation. The structure of tbADAT2 discussed below confirms
previously known details about ADAT2 and provides several key insights about paths
forward. This discussion will proceed in several parts to highlight the process of
crystallizing the protein, determining the structure, and interpreting the structure in the
context of pertinent extant literature. The discussion will conclude with a description of
several experiments that are immediately relevant and propose a path forward.
The purification and crystallization of tbADAT2.
Recombinant expression of full-length tbADAT2 (wt) in E. coli was initially problematic
with low expression, poor solubility, and aggregation, which on SDS-PAGE revealed a
discrete laddering of the protein bands characteristic of inter-chain disulfide formation.
An empiric approach of sequentially testing single Cys-to-Ser point mutants identified
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Cys117Ser as a key mutation that solved all the initial problems of protein expression and
purification. This residue is located in one of three notable insertions in the tbADAT2
sequence relative to the sequences of previously crystallized bacterial ADAT and
hsADAT2 homologues. (Fig. 6.2 A-B) In retrospect both Cys117 in loop B and Cys178
in loop C suggest themselves as potential candidates for problematic cross-linking targets
since both are located in regions of non-homology to other successfully crystallized
proteins and both are in regions with no secondary structure prediction. Cys178 was
never tested to determine if it too would alleviate the undesired cross-linking. Clearly
empiric approaches are still necessary to assess difficulties in protein expression, but such
an analysis could intelligently guide the process in general cases and could be useful in
future crystallization attempts with the ADAT2/3 heterodimer.
Purification of tbADAT2 C117S (tbADAT2) for crystallization was very successful
yielding a well-behaved, non-aggregating protein sample that did not show evidence of
background disulfide formation. Gel filtration supported the conclusion that tbADAT2
exists as a dimer in solution in vitro (Fig. 3.1C-D), a result consistent with similar
observations in the crystal structures of bacterial ADAT and hsADAT2 and with
published experimental data 38; however, oligomerization was never assessed at
low/physiologic protein concentrations. Purified tbADAT2 was highly soluble and could
be concentrated above 100mg/ml without evidence of aggregation on gel filtration, and
crystallization screening of tbADAT2 was conducted at both 50 and 100 mg/ml. The
initial conditions that were eventually optimized to produce data quality crystals were
only successful at crystallizing tbADAT2 at the higher of these two concentrations, a
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level that would rarely be considered for initial screening, which simply emphasizes the
truly empiric nature of the technique.
Diffraction data from initial crystallization attempts was problematic in several respects.
The resolution of the data was low at 3.2 Å, was highly mosaic, and was highly
anisotropic. Additionally, attempts to identify an anomalous signal for SAD or MAD
phase determination were unsuccessful. Without anomalous data, a molecular
replacement solution was attempted to solve the structure of tbADAT2 using the 3.2 Å
data followed by several rounds of automated model building. A solution was found, but
the quality of initial maps did not suggest a well-refined model would be attainable.
Structural anomalies were present in these initial models that were inconsistent with the
core cytidine deaminase fold in general and specifically within the region of the zinccoordinated active site. All the published structures of bacterial ADAT and hsADAT2
contain an active-site zinc coordinated by the PCIMCA...HAE motif that is very well
ordered with continuous detailed density. Even with the low 3.2 Å resolution of this data
in mind, the initial models based off the molecular replacement solution for tbADAT2
showed significantly distorted topology around the active site and did not show a clearly
identifiable zinc ion that was separate and distinct from the peptide chain. Moreover, an
inspection of the remaining regions showed the initial model harbored many regions of
poorly built structure and regions that were obviously outside of clear density. While it is
possible that manual model building and further rounds of refinement could have
improved upon the initial molecular replacement results, it seemed clear that the final
solution of such efforts would have yielded very little return and an alternate course was
chosen. The values for the unit cell of these crystals, the contents of the asymmetric unit,
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and the final space group were all significant data points, but cleaner data at higher
resolution were required to move forward.
As a way to increase order in crystals, Lusty et al. have shown gentle glutaraldehyde
cross-linking introduced into the crystallization experiment through vapor diffusion has
been quite successful for several test cases.73 To test whether the poor data quality for the
first round of data collection was the result of a similar disordered crystal pathology,
tbADAT2 crystals were cross-linked to varying levels; however, no improvement in the
quality of diffraction was observed, and in many cases the quality of diffraction
significantly decreased.
Another strategy to optimize diffraction was pursued through modification of the
crystallization conditions and cryoprotection techniques. Na/K tartrate as a precipitant in
the crystallization conditions opened the possibility to use high concentrations of organicacid salts as cryoprotectants, which given their presence in the crystal initially, would
putatively be less disruptive during cryo-cooling and thus improve the data quality over
the first crystals protected in 20%glycerol.72 Bujacz et al. have demonstrated how many
salts of organic acids – including Na/K tartrate – can be used as cryoprotectants at higher
concentrations; however the cryoprotective properties of Na/K tartrate are more difficult
to utilize because they are present only concentrations that are close to the salt’s
maximum solubility at room temperature. In the context of cryoprotection in
crystallography, an optimal cryoprotective agent is one that can be easily added to the
crystallization conditions in addition to the necessary reagents for initial crystal
formation. In the case of ADAT2 crystallized with Na/K tartrate at 4˚C, the
crystallization conditions were such that there was not sufficient “room” in the mothor
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liquor to achieve sufficiently high Na/K tartrate concentrations by adding a maximally
concentrated Na/K tartrate stock solution. Even attempts to reach the desired
concentrations using solid reagents proved unsuccessful. Attempts to transfer crystals
into the highest possible tartrate conditions or into cryoprotectant conditions containing
other combinations of organic salts failed to achieve a satisfactory result using data
quality and diffraction resolution as endpoint criteria. One concern with these
experiments was the possibility that the transfer into these alternate buffers or even into
higher Na/K tartrate conditions was simply too rapid. A solution to address this concern
was serial transfers between conditions of gradually increasing concentrations of
cryoprotectant; however, this approach yielded similarly low quality results likely
attributable to the destabilizing effects of the cryoprotectants in general or specifically to
an excessive amount of manipulation of the crystals required for these protocols. After
the failed attempts described above, an alternate approach was to perform the transfer to
higher salt via a vapor diffusion method that is more analogous to dehydration protocols.
The cryoprotection technique of dehydration has been shown to improve and/or preserve
the diffraction quality of crystals to a dramatic extent, and coincidentally has been shown
to be beneficial in the recent structure of S. mutans deoxycytidylate deaminase, another
member of the CD superfamily.75, 78, 79 A modified protocol was developed that utilized
Na/K tartrate as the dehydrant and allowed for minimal handling of the crystals while still
using Na/K tartrate as the cryoprotectant. Crystals prepared in this way showed
improved diffraction, lower mosaicity, and decreased anisotropy compared with the
glycerol cryoprotection approach.
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Data Collection and Processing.
Data were collected from more than 30 crystals of tbADAT2 cryoprotected in Na/K
tartrate in order to identify the best crystals for data diffraction. Significant heterogeneity
was seen across the samples both in terms of resolution and the in the quality of
diffraction; however, even the weakest diffraction recorded amongst these crystals was
consistently stronger than what had been observed previously, indicating that the better
data quality observed in these samples was due to the dehydration/cryoprotection and not
simply due to increased screening. Another indication of improved data quality was a
detectable Zn anomalous signal. Several structures of ADAT2 homologues have been
solved using Zn-MAD phasing methods 30, 31, 75, so the presence of zinc fluorescence in
the crystal indicated that a de-novo structural solution for tbADAT2 might be possible.
For a data collection strategy, SAD was selected over MAD for several reasons. First
was simply a practical consideration for maxiammly efficient use of beamline
availability. Second was the observation that only 3-4 of the crystals yielded the best
data, so the best strategy was to use the best two crystals to collect one dataset at the ZnPeak and one dataset at the optimum wavelength for the beam (highest flux), thus
measuring datasets at the maximum anomalous signal and the maximum diffraction,
respectively. Finally, examples in the literature have recently shown success using ZnSAD to solve structures of proteins with similar size and with similar Zn/amino acid
ratios as found in tbADAT2, as discussed below.80 Together these factors supported the
choice of Zn-SAD as the best possible approach given the experimental scenario.
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Structure Determination
Scaling the Zn-SAD dataset revealed a measurable anomalous signal extending to a
resolution of 4.0 Å, and the initial phase solution identified 8 pairs of zinc atoms per unit
cell (two per asymmetric unit) with a space group consistent with the initial scaled data
and with the previous low-resolution molecular replacement solution. The initial phases
from the Zn-SAD experiment combined with a higher resolution native data allowed the
de novo structure of tbADAT2 to be built and refined with reasonable statistics (see
below). The application of Zn-SAD in this instance highlights an emerging crystallophic
method that deserves note.
Zinc phases in theory
Since the technical advancement of tuneable synchrotron x-ray sources, MAD and SAD
phasing have yielded a trove of methods with which to solve crystallographic phases.81, 82
Both for its ease of use and for its general applicability, the predominant application of
these techniques has been through the use of seleno-methionine containing protein
samples prepared from methionine auxotroph strains of bacteria. Such an approach can
significantly increase the likelihood that an anomalously scattering heavy atom is in an
ordered region of the structure. The allure of such “engineered” heavy atom sites is
understandable, especially when compared to the relative uncertainty and limited
practicality of soaking heavy metal ions into crystals. Nevertheless, difficulties with SeMet derivatization do arise and can often be cumbersome and time-consuming to address
if not altogether impossible. Given the relatively weak strength of the anomalous signal
from selenium and the added flexibility of the methionine side-chain, the overall phasing
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effectiveness of Se-Met is generally accepted to be no more than 1:100, heavy
atoms:amino acids.83 In proteins with low methionine content or in proteins in which the
methionines are located in highly mobile regions of the structure, the MAD or SAD
anomalous signal from Se-methionine can be insufficient. Finally, Se-methionoine
substituted protein is frequently more difficult to purify and often requires an additional
round of crystallization optimization. Of course the process of phasing data in
crystallography is an empiric one, and if Se-met substitution doesn’t work, researchers
will continue with other techniques until a successful approach has been found; however,
judging by the relative lack of structures solved by either MAD or SAD techniques using
the anomalous signal of zinc, it would appear as though the use of zinc anomalous
phasing has been overlooked when in many instances it may have proven quite powerful
and perhaps much more expedient. This discrepancy begs the question: why use SeMAD/SAD when a much more direct solution is available?
Zinc, despite having a similar-strength anomalous signal to selenium, and despite the
native presence of structural and/or enzymatic zinc ions in a large number of proteins, is
used infrequently with respect to selenium for MAD and even less so for SAD phase
determination. There are many cases in the crystallography literature and several within
the extant structures of the cytidine deaminase family where Se-methionine phasing has
been used despite the presence of one or more structural ordered zinc(s). The reasons for
this may be simply historic since it is a trend that appears to be changing as more
structures solved by Zn-based phasing are reported in the literature. The crystallography
field continues to explore the boundaries of anomalous phasing methods using many nonselenium heavy atoms for MAD and SAD experiments, many of which could be
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considered first-line approaches, i.e. they take advantage of the native elements of the
crystallized protein. Among these elements zinc is by not particularly unique for any
physical property save for its relative abundance, and it is discussed in depth here simply
as an example of an emerging trend and specifically because it was utilized in the
structure determination of tbADAT2.
A more thorough experimental treatment of this idea has been provided by Dauter,
Dauter, and Dodson, who in 2002, revisited fifteen previously solved structures and
solved them anew using SAD methods phased off the anomalous signals of many
different heavy atoms including two structures with native zinc and seven more with
atoms natively incorporated into the crystallized proteins.84 Dauter et al. discuss not
only the broad applicability of the methods but also how the computational advancements
over the last ten to twenty years – specifically solvent flattening and density modification
algorithms – have improved the phasing power of anomalously scattering heavy atoms.
Perhaps at the risk of belaboring the point, the results of Dauter et al. do not imply this
progress in computational power has independently prompted the use of non-selenium
heavy atoms, they simply demonstrate how all SAD and MAD techniques benefit from
these computational techniques and are included in this discussion to highlight the
potential for non-selenium SAD/MAD phasing.
The Fu group at Cornell have recently made careful studies using zinc-based phasing
techniques to demonstrate the applicability of its use in de novo structure determination,
the results of which show that in addition to being abundant zinc can also be quite
powerful as a phasing tool relative to other elements. Meyer et al in 2006 and 2009 have
demonstrated the use of zinc MAD85 and SAD86 phasing to improve the resolution of
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RNA polymerase II to 4.1 and 3.8Å, respectively. These efforts demonstrate an
impressive experimental phasing effectiveness of 1Zn:550 amino acids, which according
to the authors’ theoretical calculations could potentially extend to 1:1100, almost an order
of magnitude beyond the power of Se-methionine. These authors further highlight
several recent structures that have used Zn-MAD methods successfully with phasing
effectiveness extending to 1:368 in other cases. A literature search identified several
additional examples that have utilized Zn-SAD with phasing effectiveness ratios in the
range of 1 zinc2:00-300 amino acids.80, 87, 88 Again, these results are discussed alongside
the Zn-SAD approach in the present tbADAT2 structure not to identify a new
technological contribution, rather they are presented to demonstrate how this is an
underutilized technique that will likely become much more common as the ease of use
and overall phasing power available through zinc phasing is appreciated. Phasing with
zinc is easily accessible at synchrotron-wavelength x-rays, and it is a technique that
should be considered more frequently as a tool for de novo crystallography.
Zinc phases in practice, the structure of tbADAT2
For tbADAT2, the initial zinc phases yielded interpretable electron density maps that
allowed 157 of the 225 residues of each monomer to be built through a combination of
automated and manual model building. Density for the model was discontinuous with
two significant breaks occurring at points that corresponded to insertions in the tbADAT2
sequence. (Fig. 5.4) Many attempts were made to build these regions; however, each
attempt resulted in a model that 1) failed to improve the overall refinement stastics and 2)
harbored problematic geometric statistics that were unresolvable. The final model
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represents density that could unambiguously be interpreted using 2Fo-Fc maps contoured
at 1σ
The phases of this initial model were refined against higher resolution data with the
intention of improving the refinement of the model and extending the buildable portions
of the model at the border regions of the discontinuities in electron density. These
attempts succeeded at the former but not the latter of these two objectives. The maps
resulting from these efforts showed small improvements in the sharpness of side-chain
detail in some regions of the density, but overall the difference was limited. The main
effect of the high-resolution data was to improve the overall refinement statistics of the
structure. This process was not direct and involved several different approaches to data
processing and refinement. The final combination of anomalous refinement on
anisotropically scaled data with the use of TLS parameters was built up stepwise to
produce for the final refinement strategy.
First among these approaches was the decision to treat the high-resolution data as an
anomalous dataset. This data was collected at the optimum wavelength for peak x-ray
flux for the X29 synchrotron beamline at NSLS, which at 1.070 Å lies in a region of the
x-ray spectrum in which zinc atoms have a measurable anomalous signal. Typical
scaling of this data using an I/σI cutoff of 2.0 resulted in an overall diffraction limit of
2.56 Å. Rescaling the data to include an anomalous signal decreased the overall
resolution of the dataset from 2.56 to 2.69Å, but anomalous refinement with this data did
show improvement in the overall refinement statistics. Visual inspection of the
diffraction data had revealed diffraction to nearly 2.4Å, so the need to truncate this
dataset at 2.56Å and then at 2.69Å for anomalous scaling prompted a more detailed
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analysis in an effort to reclaim some of the higher resolution data that had been lost to
truncation.
Anisotropic diffraction was one of the original problematic aspects of the initial
tbADAT2 dataset at the initiation of this project. While the anisotropy in subsequent data
was definitely improved by the cryoprotection techniques above, anisotropy was still
evident in the high-resolution data and was significant enough to be visibly detectable,
e.g. obvious diffraction extended to 2.4 Å in the strongest dimension and to about 2.7 Å
in the weakest. Strong et al. have developed web-servers for the application of
techniques they developed to address an extreme case of anisotropic diffraction they
recently encountered.48 Briefly the calculation applies an ellipsoidal truncation to the
diffraction data and applies a negative thermal (B) factor to the remaining data to
accommodate for global effect of the lost data, so the typical sphere of reflection with a
radius of 1/resolution (Å) now has ellipsoidal dimensions of 1/resolution(a) (Å) x
1/resolution(b) (Å) x 1/resolution(c)(Å). (Fig. 7-1A) The difference in volume of these two
shapes is the basis for an artificially low data completeness seen for the anisotropically
truncated data used for the structure determination of tbADAT2 (Table 3.1) and is similar
to statistics seen in the deposited data from Strong et al. A rigorous method for
calculating data completeness within the ellipsoid was not available, however an
approximation based strictly on the volume of the sphere of reflection for ideal data with
a resolution of 2.5Å (r=1/2.5) and an ellipse with dimensions corresponding to a
resolution of 2.8x2.8x2.5 (axbxc =1/2.8x1/2.8x1/2.5) yields a ratio of 1:0.77
Vsphere:Vellipse, (Fig. 7-1B) which would indicate that a value of 80.1% calculated for this
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data equivalent to a nearly complete dataset for the data within the limiting boundary of
the ellipse.

Figure 7-1. Schematic of anisotropic data truncation showing A) the differences in cross
section between spheres of reflection with radii of 1/2.8Å (green) and 1/2.5Å (red) and an
ellipsoid (blue) with dimensions 1/2.8Å x 1/2.8Å x 1/2.5Å cut along the longest
dimension. B) The ratio of volumes between the three shapes is shown in B, with all
volumes relative to the largest sphere.
Strengthening this conclusion is the calculation for completeness (>99%) for a normal
spherical truncation of these data at 2.8Å. The anisotropic truncation can be performed
on native or anomalously scaled data, so here the data were first scaled anomously to
2.5Å and then truncated ellipsoidally. This approach maintained the beneficial
refinement effects of the anomalous data while also preserving as much of the collected
data as possible. Combined, these two strategies yielded a 4-5% improvement in Rfree.
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The third parameter of refinement focused on optimizing the model used for refinement
as opposed to the reflection data. Given the asymmetric unit comprised a single
homodimer, initial refiment parameters were utilized that applied non-crystallographic
symmetry to the model. This approach showed promising refinement statistics, so the
additional technique of TLSMD analysis (torsion, libration, and screw motion
determination) was utilized in which the starting model for refinement was analyzed for
rigid body segments within the structure that have equivalent TLS motion, e.g. an αhelix, or a pair of β-sheets. The definition of these segments was then used for TLS
refinement prior to secondary rounds of restrained refinement.
The final combination of these TLS refinement against the high-resolution dataset scaled
anomously and truncated anisotropically was used for the final rounds of refinement,
which resulted in a final model with an Rfree/Rwork of 29.6/25.8.
Structure analysis
The asymmetric unit of the tbADAT2 crystal structure was found to be a symmetric
homodimer, a result in agreement with predictions based on gel-filtration data (above and
89

). As was expected from initial sequence homology, the tbADAT2 structure closely

resembled the hsADAT2 structure and exhibited identical topology to the published
bacterial ADAT structures in the region of the canonical CD fold. Structural alignments
of the individual tbADAT2 monomers with bacterial ADAT and hs ADAT2 reveal
r.m.s.d values of 1.3 and 1.9 Å2, respectively. The dimer interface of tbADAT2 also
shows significant similarities with the bacterial and human ADAT structures. As in the
published ADAT structures, the tbADAT2 dimer interface is formed largely by a
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symmetric interaction between the three α-helices in each monomer that contain the zinccoordination motif; however, the specific orientation of the tbADAT2 interface differs
from the known bacterial ADAT and hsADAT2 structures. It is important to note that
some variability exists with regard to the dimer interface across all the known ADAT
structures. While no specific attribute of ADAT function has been correlated with this
observation, it is interesting to note that relative to one another, the tbADAT2 dimer
interface is rotated to the largest degree in pairwise comparisons between the known
structures: i.e. when a structural alignment of all the ADAT dimer structures is performed
using just one monomer of each dimer, the specific monomers align very well, but the
unaligned monomers of each of the dimers are rotated to a degree compared to the other
structures with the ultimate effect being the separation of the two active sites in the
monomer relative to the least rotated structure. The significance of this rotation awaits
further study, but it could be part of a structural reason for tbADAT2 inactivity towards
tRNA, or it could serve as the basis for a mechanism to accommodate non-tRNA
substrates.
Like the hsADAT2 structure, the tbADAT2 structure shows a highly conserved and
physiological zinc binding motif when compared to other bacterial ADAT structures.
This would seem to negate initial speculation that the reason for inactivity is due to a
distorted or somehow altered catalytic site. (Fig 6.1C) There is no structural reason
evidenced in the catalytic core for either tbADAT2 nor hsADAT2 to be inactive. While
the tbADAT does not show a catalytic water coordinated to the zinc, the lack of a refined
catalytic water in the present structure is most likely attributable to the relatively low
resolution of the diffraction compared to the structures to which it is being compared.
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The only distinctive feature within the active site of tbADAT2 is the presence of Tyr145,
which is contributed to the active site from the opposite monomer. The presence of a
residue in this same location is typical in these structures (Fig. 7.2), but tyrosine in this
case stands out as it is bulkier, less hydrophobic, and is oriented such that an interaction
with the 2’-hydroxyl of the ribose could be possible. Again, the significance of this
particular residue is moderated by the observation that the hsADAT2 contains a small,
more hydrophic leucine in this position and is still inactive toward tRNA.

Figure 7.2

Active site of tbADAT2 showing presence of Tyr from the opposing

monomer. tbADAT2 is in magenta and Tyr is light blue and labeled as such. Additional
aligned structures are shown for comparison: saADAT2 with substrate (cyan), atADAT2
(orange) and hsADAT2 (purple). Stereo view in Appendix I.
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The second possible explanation for inactivity involves the affinity for the substrate. A
structural comparison with the saADAT structure bound to stem-loop substrate analogue
shows that several residues involved in RNA binding have undergone non-conservative
mutation in the tbADAT2 (Table 6.1, Fig. 6.3B) The mutated residues in tbADAT2
correspond to residues in the saADAT structure that provide both specific and nonspecific interactions with the RNA molecule. The importance of these residues in the
saADAT structure is clear as they provide very sequence-specific interactions with the
RNA substrate; however the importance of these contacts in ADAT2 is still an open
question. It is clear that several key residues are not conserved in the tbADAT2
structure, and that the more extreme mutations – E-to-A and R-to-G – lie on the face of
the opposing monomer to the one binding the catalytic zinc. (Fig. 6.3B on the right in
cyan) Collectively these mutations support the conclusion that ADAT2 has evolved away
from the substrate binding strategies of prokaryotic ADATs; however, it is important to
note that it cannot be concluded that these mutations are the reason ADAT2 no longer has
affinity for tRNA substrates. It has been shown recently that mutations in several of the
conserved substrate binding residues, specifically E92 and K159, in the context of the
ADAT2/3 heterodimer did not affect tRNA binding.33 It is also worth noting that the
region harboring the E-to-A and R-to-G mutations mentioned above would be replaced
by ADAT3 in one of the two active sites in the heterodimer. From these results it is fair
to conclude that bacterial ADATs and the ADAT2/3 of higher eukaryotes utilize
strikingly different strategies to bind substrate, which would appear to have made the
conservation of the residues involved in RNA binding in bacterial ADATs unnecessary
for the purpose of binding tRNA. A consequence of this, however, is an ADAT2 enzyme
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that no longer binds tRNA substrate due to an as-of-yet unknown reason. It seems
plausible that it is due to the mutations alone, and an interesting proof-of-principle
experiment would be to attempt to restore tRNA binding in tbADAT2 by restoring these
mutations to the consensus residues in the ADAT structures. This would account for the
same loss of tRNA binding in both the hsADAT2 and tbADAT2 homologues and would
be a simple experiment to attempt in both cases. This explanation alone, however, does
not leave much room to explain the novel functions that have been attributed to ADAT2
and the ADAT2/3 heterodimer.
To futher investigate these novel functions – specifically the in vivo C-to-U editing at
position 32 of tRNA and in vitro C-to-U editing of DNA – the most likely candidates
from a structural approach are the three distinct insertions in the tbADAT2 sequence.
(Fig. 6.2A). These insertions are unique to the trypanosomatid enzymes and therefore
stand as good candidates in which to identify a structural basis for these unique
enzymatic features and may, additionally, suggest mechanisms for substrate recognition
and the purported domain swap.
Two of these three loops are found on the face that is oriented toward the approaching
substrate, and of these, only loop A is ordered. (Fig. 6.2B-C) The high thermal factors of
loop A along with the lack of specific secondary structure and the lack of ordered
electron density for loop B both indicate these two sub-domains are highly flexible, and
given the length of both of these loops, have the capacity to sample a large range of
conformation space near the catalytic site of the enzyme. With the proximity of loop B to
the active site, this flexibility could easily be a mechanism by which substrate is
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prevented from binding, and when open could create an extensive binding surface
accommodating a wide variety of substrates.
The APOBEC cytidine deaminases are a group of enzymes that have been of intense
focus due to their involvement with a number of important biological functions mediated
by modification of DNA and RNA in higher mammals. Recently several structures of
this family have been determined through x-ray crystallography and NMR, and while
insightful, the mechanisms for substrate recognition and binding have yet to be
completely elucidated.90 APOBEC-3G is an interesting example of this family that binds
ssDNA and RNA and provides innate viral immunity by interfering with viral replication
within the cell. The structure of APOBEC-3G was recently solved by X-ray
crystallography.91 This structure revealed a series of loops on the surface adjacent to the
active site zinc of APOBEC-3G, which have been proposed to create a DNA-binding
cleft oriented towards the active site zinc. A structural alignment of APOBEC-3G and
tbADAT2 clearly shows that these loops are oriented in much the same way as the loops
of tbADAT2 (Fig. 7.3). APOBEC and ADAT families are not directly related and belong
to different clades of the CD superfamily, so any similarity likely represents two
independent evolutionary adaptations; however, the similarities are intriguing and
certainly provide a basis for the possibility that the tbADAT is an active enzyme for
which the substrate has yet to be identified. Moreover, the presence of APOBEC proteins
in higher mammals could explain why hsADAT2 does not show the same modifications
as the tbADAT2 of this study, since these enzymatic functions have been accommodated
in the human cell by additional enzymes that are notably absent in lower eukaryotes.
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Figure 7.3

Alignment of APOBEC-3G and tbADAT2.

APOBEC-3B is in green,

tbADAT2 in magenta and blue. Loops A bnd B are colored for electrostatic potential as
are the active site residues within 7Å of the active site zinc of the blue monomer. Stereo
view in Appendix I.
Another interesting possibility for the function of these loops relates to the proposed
domain swap model proposed for tbADAT2. The domain of tbADAT2 purported to
swap with an analogous domain from ADAT3 begins in the middle of the disordered
region of loop B. The original models for the domain swap were created using the
hsADAT2 as a starting model, which specifically does not have the extra loop in this
region. Consequently, these models show the stretch of amino acids connecting the
swapped and un-swapped portions of hsADAT2 in an almost linear configuration with
very little freedom of motion. (Fig. 1.3B) tbADAT2 has ten additional residues in this
region, and therefore, it would seem to be able to more easily accommodate this domain
swap with less strain on the intervening loop. Another interesting consequence of such a
domain swap occurring at loop B would be the minimization of this loop as it is stretched
from one monomer to the other resulting in a significant difference in the ADAT2
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binding surfaces in these two conformations such that substrate binding by tbADAT2 in
the homodimer would be significantly altered in the heterodimer configuration. Given
that this loop is not structured in the present model, the possibility that a domain swap
occurs in the tbADAT2 as well can’t be definitively rejected. A series of disulfide crosslinking experiments have been designed and are presently being pursued, but the
preliminary data from these experiments has yet to show any conclusive results.
Of the structural features identified in the tbADAT2 structure, loops A and B are of the
greatest interest as they are both situated to potentially alter the substrate binding surface
of the protein and/or participate in a domain swap. Several powerful tools are available
to test the degree to which these loops are essential for activity and will be the future aim
of this project. First would be to assess the importance of each loop independently both
in vitro and in vivo. Many of the published experiments could easily be revisited using
recombinantly expressed ADAT2 either alone or in the context of ADAT3 with varying
levels of alteration to either of these loops. Since ADAT2 is essential in T. brucei,
viability studies could be performed on strains that had a mutant ADAT2 allele with
subsequent insertional knockouts or inducible RNAi downregulation of the wtADAT2
allele. These experiments would be further complimented by a more careful study of
other examples of eukaryotic ADAT2 and ADAT3. Activity profiles of non-T. brucei
enzymes are essential before a definitive role can be assigned to any particular domain.
To date much of what is know about tbADAT2/3 has not been shown absent in other
ADAT2/3 enzymes. The ability to clearly identify features of these enzymes will require
a much more careful analysis of representative members of the eukaryotic ADAT family,
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with the hsADAT2/3 enzymes being the most instructive specifically due to the absence
of the loops A and B in the hsADAT2.
Another critical focus of continuing research will be the determination of eukaryotic
ADAT2 homodimer function. The lack of a known function in eukaryotes in the
presence of such a clear function in the prokaryotic homologues presents an interesting
and complex question. The structures of hsADAT2 and the above tbADAT2 both
demonstrate that eukaryotic ADAT2 clearly has the capacity to form a homodimer with
an interface highly similar to bacterial ADAT and nearly identical in topology and buried
surface area.

The details of the dimer interface along with the demonstrated in vitro

stability of the homodimer necessary to obtain the crystal structures of these proteins
provide indirect evidence that a stable homodimer could exist in vivo, something for
which direct evidence is still lacking. The function of such a homodimer remains to be
clearly illucidated; however, the structure of the tbADAT2 homodimer presented above
clearly exhibits features of the canonical cytidine deaminase active site with appropriate
zinc-coordination and side-chain geometry. Save for occlusion of the active site by the A
and B loops discussed above, there seems to be no structural reason to suggest that the
tbADAT2 would be unable to catalyze substrate. Whether that substrate is a modified
tRNA, or some other nucleic acid substrate remains to be determined. Several
approaches to identifying such a substrate are currently underway, including attempts to
identify possible DNA and RNA substrates.
The structure of tbADAT2 homodimer presented above reveals an enzyme harboring the
canonical cytidine deaminase core fold and an otherwise normal functional appearance
with no obvious indications as to why this enzyme is inactive. The structure suggests
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several interesting possibilities as to why substrate binding is impaired in this structure
including a rotated dimer interface and the presence of unstructured loops adjacent to the
active site, but explanations for the inactivity of the enzyme remain elusive. The
presence of these loops provides an intriguing possibility that structural features unique to
tbADAT2 allow for a more diversified substrate profile, perhaps via mechanisms similar
to those proposed for the AID and APOBEC family of proteins. The function of loop B
may also be to facilitate a putative domain swap when hetero-dimerizing with ADAT3,
allowing the constitution of a functional active site with the essential Glu92 proton
shuttle of ADAT2 with the essential zinc binding residues of ADAT3. Together these
results provide the guide for several interesting lines of investigation toward additional
substrate identification in the homodimer as well as a helpful model with which to assess
the function of the ADAT2/3 heterodimer. Significant work remains in order to
determine the degree to which the results in tbADAT2/3 are unique to T. brucei vis-à-vis
other eukaryotic ADAT2 and ADAT3 homologues. Specifically, are the alternate
substrate profiles seen in vitro for the T. brucei enzymes reproducible with ADAT2/3
from other organisms? The hsADAT2 homologue does not have the same insertional
loops as tbADAT2 but is otherwise highly homologous to the tbADAT2, so there is an
interesting possibility that the results from T. brucei are indeed unique and attributable to
the loops identified above. An important question will be to determine if the possibility
of a domain swap is unique to T. brucei or a more widespread phenomenon in
eukaryotes. The suggestion that loop B facilitates a domain swap due to its added
flexibility could be strengthened by evidence that such a swap is not indicated in other
organisms and could provide a clear path of experimentation to further understand the
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mechanism of this fascinating possible mechanism. Finally, a full understanding of many
of these questions awaits greater structural detail of ADAT3. No structural data is
available to date for ADAT3 in any organism; furthermore, in addition to the domain of
ADAT3 that is highly homologous to ADAT2, ADAT3 possesses an additional 160
residue N-terminal domain that has very low sequence similarity to other proteins. The
structure and function of this additional domain is completely undefined and will be an
important piece of data in the global understanding of the questions raised in the above
discussion. Initial attempts to explore the solubility of this N-terminal domain have been
successful and suggest that structural studies of this domain can be pursued in parallel
with studies of ADAT2/3.
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Appendix I
Stereo Views. The following are stereo views of figures from the results and discussion.
They are numbered and arranged according to their appearance in the text. Figure
legends are found in the body of the text.

Figure 6.1C.
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Figure 6.4

Fig 6.5 No-Swap
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Fig 6.5 Domain Swapped

Fig. 7.2
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Fig 7.3
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Appendix II:
The following is a summary of three additional projects that have formed the balance of
my PhD research in the Stebbins lab. All three address issues of the structure and
function of virulence factors from bacteria, exploring questions of how bacterial
virulence factors function and how this function informs our understanding of the cells
and organisms these bacteria infect. The first, work with Senior Research Associate
Dragana Nesic in the Stebbins lab, resulted in the crystal structure of Helicobacter pylori
virulence factor CagA bound to and inhibiting the human MarkII kinase.92 For this
project, my contributions will be presented in the results section and discussed in the
context of the work Dr. Nesic and others contributed to this paper. The second and third
projects involve the virulence factors SopB and YpkA from Salmonella and Yersinia,
respectively. These projects did not result in publishable results to date. They will be
presented with individual introductions, results, and discussions.
CagA from H. pylori
Introduction
Helicobacter pylori is a ubiquitous stomach pathogen found in humans at a prevalence
ranging between 20-90% in regions across the globe, and in total it is believe to infect
around 50% of the human population. H. pylori are unique in their ability to colonize the
stomach where the resulting infection is typically asymptomatic. This observation was
the basis for the contention against Warren’s and Marshall’s claim that these bacteria
were a causative agent in peptic ulcer disease and a significant risk factor for the

!

92

development of gastric carcinoma, claims that proved to be correct and for which the pair
were awarded the Nobel Prize in Physiology or Medicine in 2005.93, 94
H. pylori utilize a type IV secretion system to transport the 120-145 kDa cytotoxic
associated gene A (CagA) protein into host cells 95, which increases the liklihood and
severity of the gastrointestinal pathology of this pathogen.96 Infection with CagA+ H.
pylori strains correlates with the incidence of premature myocardial infarction97,
atherosclerotic plaque build-up and stroke98, and microalbuminuria in type II diabetes99.
The direct link between the action of CagA and these pathologies is an area of active
research focused on the many different cellular targets of CagA (for review, see MurataKamiya 2011).100
A major focus of CagA research has been to understand the function of the C-terminal
region of the protein harboring the so-called EPIYA repeat domains (named repeat A-D),
which vary in number and combination in a strain-specific manner.101, 102 These repeats
interact with the partition-defective and microtubule affinity-regulating kinase (PAR1MARK) family of protein serine-threonine kinases.103 PAR1 has a role in maintaining
tight-junctions and cell polarity, so the disruption of normal PAR1 function has the
potential to result in a significant disruption of normal endothelial function.
Results:
Dr. Neic identified a 120 amino acid domain of CagA comprising EPIYA repeats A, B,
and C, which formed a stable complex with PAR1 and crystallized at 10-25 mg/ml via
vapor diffusion when reductively methylated and set up in 2:1 drops over 22.5-
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25% polyethylene glycol (PEG) molecular weight 3350 Da, 300 mM Li2SO4, and 100
mM Bis-Tris pH 5.8-6.2, at 23ºC. Initial diffraction was recorded to ~2.8Å on an inhouse x-ray source, and the diffraction data showed a very tightly spaced pattern
suggesting a very long unit cell edge. This data proved very difficult to index and
process, and closer inspection of the diffraction pattern revealed what appeared to be
duplication of the pattern instead of a true long unit cell edge. The initial cryoprotection
protocol of direct transfer into the crystallization buffer containing 5-10% PEG 400 and
7% glycerol was modified by introducing a step-wise increase, my introducing varying
lengths of incubation at each step, changing the number of steps, and changing the
method of cryo-cooling, e.g. LN2, cold-stream, liquid ethane. These various techniques
did not significantly alter the diffraction pattern. Assuming a long unit cell, several data
collection strategies were attempted with the aim of orienting the crystal in a plane
perpendicular to rotation axis of the goniometer. These included the use of arc
goniometers in-house and the use of a kappa offset goniometer on beamline X29 at the
synchrotron. These results did not change the general diffraction pattern, which
strengthened the conclusion that gross crystal morphology was the likely source of the
poor data quality.
The crystallization drops for CagA-PAR1 were heterogeneous with the supposed “best”
crystals representing only 10-20% of the total number of crystals in each drop. These
best crystals were used for the above experiments and were selected for size (~0.2-0.3mm
in all dimensions), regularity, and thickness. The conclusion above regarding crysal
morphology prompted the screening of many different crystal sizes and forms in the
initial crystallization drops. The same cryoprotection techniques as above were again
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used in various combinations and high quality diffraction data without the tight splitting
was obtained from crystals that were square thin plates with edges ~0.15mm. Several
crystals of this form were cryoprotected by serial transfer into the above cryo-buffer in 34 step-wise increments and flash-cooled in LN2. Diffraction data from these crystals
showed diffraction to 2.2Å that was regular and without the splitting morphology seen
previously.
Discussion:
The diffraction data collected at the synchrotron allowed the structure of CagA-PAR1 to
by solved by molecular replacement using the previous PAR1(PDB ID 2HAK)104
structure as a search model. The structure revealed that all but 14 residues of the CagA
sub-domain were ordered in the structure and formed an extended coil that bound the
active site of PAR1 as a substrate mimic. These results were surprising for several
reasons, first of which was the lack of the EPIYA motif in the bound sequence of
interpretable density and for lack of density for the remainder of the CagA peptide.
Analysis of the crystallized protein by SDS-PAGE confirmed the full CagA construct
was present in the crystals, but whether it interacts in a specific way with the kinase
remains unknown. Structurally, the results were quite interesting as CagA was shown to
trap PAR1 in a pseudo-active state in which the lobes of the kinase hinge toward one
another and the activation loop of the kinase adopts an activated conformation as though
Mg2+ and ATP are present, despite the lack thereof. Together these results show how a
very small domain within CagA is sufficient to effectively inhibit PAR1
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Type III Virulence Factors SopB of Salmonella and YpkA of Yersinia
Introduction to Type III Secretion Systems
Numerous species of Gram-negative bacteria exhibit a syringe-like organ likely evolved
from the flagellar apparatus that facilitates complex interactions between the bacterium
and its specific host and is essential for virulence, pathogenicity, and in some cases even
symbiosis.105 Termed type III secretion (TTS), this mechanism of virulence was first
identified 21 years ago when evidence for secretion of virulence determinants in Yersinia
spp. was shown that was independent of either N- or C-terminal signal-sequences and
lacked sec-dependent signaling. This secretion activity was found to rely on the
expression of a large operon consisting of at least 13 genes – a list that would later be
expanded to more than 20 – and be found to comprise the proteins necessary for the
formation of the syringe-like needle complex.106-108 In the first years following the initial
discovery, TTS was quickly identified in many well-known Gram-negative bacterial
species that cause significant disease in humans, domesticated animals, and essential food
crops.109 Much about TTS has been learned in the intervening years about both the
function of the secretion apparatus and about the virulence factors that are transported via
this mechanism. A web-based database has been established to, among other things,
simply track and normalize the nomenclature of this field of research as it continues to
grow. A quick inspection on the database of organisms that exhibit TTS and the number
of TTS virulence factors in each of these species highlights the impressive complexity
and diversity of host-microbe interactions that are mediated by this mechanism:
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Salmonella spp., for example, utilize two different TTS systems, each for a unique
purpose and each with its own set of virulence determinants; Chlymadia spp. transport
more than 25 different virulence factors into the host cell via TTS, the pan-genome of
Pseudamonas syringae contains 57 families of TTS virulence factors, and interestingly,
Rhizobium spp. utilize TTS systems to facilitate the well-known symbiosis between these
species of bacteria and leguminous plants.105, 110
TTS is purported to have arisen from a distant genetic duplication event of genes
comprising the flagellar apparatus.111 Significant similarities have been observed at the
genetic, structural, and organizational level between TTS and the flagellar apparatus.
These similarities were the main basis for the early modeling and purported functional
mechanisms of TTS,112 and evidence of significant cross-talk between the flagellar and
TTS systems strengthens such a comparison.113 Both structures exhibit a basal complex
anchored in the bacterial inner-membrane that contains within it a second structure that
spans the inner and outer bacterial cell membranes and is itself traversed by a narrow
central pore only 2-3 nm wide. In the flagellar apparatus, flagellin subunits purportedly
transit through this pore and emerge at the surface of the growing flagellum leading to
elongation of the flagellar tail.114 In the case of TTS, instead of a flagellar tail, the basal
body in the bacterial inner membrane connects to the needle apparatus, which unlike the
flagellum, is straight, narrow, and typically much shorter. The needle component of TTS
is fairly consistent between species varying between 45-60 nm and is capped at the
needle tip by a putative homo-pentamer that facilitates docking with host cell
membranes.115, 116 (Fig. Appendix II-1) Much like the case of the flagellar apparatus, the
needle appendage purportedly grows by transporting the needle subunit proteins through
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its central pore to the lengthening tip of the appendage. Once the appropriate length has
been reached, the needle complex is capped and the specificity for transported substrates
switches from subunits of the needle itself to the TTS virulence factors. (see IpaB-D in
Fig. Appendix II-1) It has been shown that specific TTS components are involved in both
the control of needle length and the control of substrate specificity, although the strength
of the interaction between these two mechanisms and the specific mechanism of signal
transduction back and forth between the needle tip and the basal body remains to be
determined.117 Such a mechanism purports that a ruler-like protein somehow measures the
growing needle (see Spa32 in Fig. Appendix II-1), and once the appropriate length is
achieved, a substrate-specificity switch occurs causing the growing needle to be capped
by a host-cell docking complex and then for virulence factor transport to begin once
successful docking with the host cell membrane is established. Such events would
seemingly require signaling events between the needle tip and the basal body to trigger
the switch in substrate specificity to stop needle growth and initiate cap formation and
then again to initiate virulence factor transport upon host-cell contact. How these events
are regulated is presently unknown. They raise fascinating questions about what types of
signal transduction could be possible in this context as well as what structural
mechanisms are utilized to control the flow of not just proteins but of ions and water.
Electron micrographs of bacteria actively expressing TTS needle complexes show
multiple needles studding the surface of the bacterium. It is interesting to consider
mechanisms that could prevent these needles from serving as a conduit for ions and small
molecules between the intra- and extracellular milieu while still maintaining the ability to
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transit large proteins; however, such mechanisms remain strictly speculative as-of-yet as
no structural data with adequate resolution to address these questions has been published.

Figure Appendix II-1 Diagram of Type III secretion needle complex assembly and
virulence factor transport. From Hayes et al. 2010.118 Protein names are from Shigella
spp. Schematic shows the assembly of of needle subunit MxiH in the presence of IpaB,
C, and D which all are critical elements for docking with and pore formation in the host
cell membrane. Spa32 has been shown to regulate needle length and substrate-specificity
switching. MxiC has been assigned a gatekeeper role on the bacterial face of the basal
body, and Spa47 is an essential ATPase that provides energy for transport.
Similar to the rotation of the flagellar apparatus, transport via TTS is an ATP-dependent
process. Mutation in Yersinia of the TTS-associated ATPase YscN not only renders
strains of Y. pestis avirulent but also allows the successful use of these strains as liveattenuated vaccines for bubonic plague in mice.119 As mentioned above, it is unclear if
there is a rotational aspect in the function of the ATPase in TTS, and if so how this would
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be linked to protein transport. The size of the central pore of the needle complex is
putatively the size of an α-helix (fig. Appendix-II D-F), so transit of TTS virulence
factors is believed to involve either an unfolding of already-translated bacterial virulence
factors or a process whereby translation and transit are coupled.120 Possible evidence for
the latter of these scenarios is found in reports that the mRNA of TTS virulence factors
contains within it sequences that target it to the secretion apparatus.121 How such a model
is consistent with the role of the TTS virulence chaperones (see below) is not clear.
Neither is it clear how the mechanism by which an ATPase-driven proton-motive force
potentiates the possible unfolding and subsequent transit of virulence factors through the
TTS apparatus. Several groups have attempted a structural approach to these questions
through different combinations of electron microscopy, crystallography, and molecular
modeling, and the “view” of these structures now extends to a resolution of sub-10 Å
(Fig. Appendix II-2); however, many of the above questions await an atomic level
description of the basal body and needle complex structures.120, 122, 123
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Figure Appendix II-2

Structure of Type III Secretion system by 3D Cryo-

electronmicroscopy. The S. typhimurium basal body at 17Å resolution is shown in A, in
cross-section in C, and with the needle complex B (from Marlovits et al. 2004)124 The
structure of the needle from Shigella flexneri is shown at 7Å resolution in longitudinal
(D), and horizontal (E) cross-section. Ribbon diagrams show a model of the needle
complex subunit fit to the experimental cryo-electron density in gray. Density depicted
in yellow is to scale for a linear α-helix, and the scale bar in D is 20Å. (from Fujii et al.
2012)120
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As exemplified by the mutation to the Yersinia TTS-ATPase mentioned above, functional
TTS is often essential for successful pathogenesis. Being unique to bacteria, many critical
pieces of the TTS machinery have stimulated intense interest as non-traditional drug
targets.125, 126 Equally interesting have been the initial successes in manipulating TTS in
order to utilize it as a drug/antigen delivery system within host organisms, particularly
higher mammals. Exploiting both the ability of bacteria to target specific cell types and
the ability of TTS to deliver large proteins directly into the host cell cytoplasm, these
experiments could provide new and unique therapies for otherwise intractable diseases by
delivering antibodies directly into host cells as a means of inhibiting abnormal cellular
pathways or potentiating senescence/apoptosis127, or by delivering disease specific
antigens to the appropriate cellular components of the immune system.128, 129
It is important to note that there is not universal acceptance of the syringe-like
mechanism of TTS translocation of effectors into host cells. Edgren et al. have recently
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argued that direct evidence of effector translocation through the needle complex has yet
to be shown. As an alternate model these authors offer a model that would involve the
needle complex serving as a docking/sensing appendage that determines proximity to
susceptible host cells. TTS effectors would then diffuse across the space between the two
cells and be transported into host cells through a mechanism similar to AB toxin
transport.130 (Fig. Appendix II-3)

Figure Appendix II-3. Model for non needle-like injection mechanism for Type III
secretion proposed by Edgren et al. in which the needle-complex is a sensing/docking
organelle that then triggers demarginilization of effector/translocator complexes that
diffuse onto the surface of the host cell and form pores that can then transport effectors
into the host cell.130
Proteins secreted via TTS and the flagellar apparatus all contain an essential N-terminal
secretion signal and putatively an additional secretion signal in their 5’ region of their
respective mRNA.121, 131 Each secreted TTS protein – including subunits required for
needle assembly – interacts specifically with one of a family of highly conserved
chaperone molecules that target the effector to the secretion apparatus and stabilize the
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effector and/or mask its activity prior to transport. Button et al. have shown how the
translation of TTS virulence factors is tightly coupled to the co-translation of the
appropriate TTS chaperone such that if chaperone translation is not present then
translation of the paired virulence factor is inhibited by an RNA-mediated mechanism,
suggesting that the genomic organization of TTS is an essential component to their
regulation.132 The nature of the interaction between TTS chaperones and their effectors is
only generally understood. There are three groups of TTS secretion chaperones classified
as such depending on whether the chaperone interacts with a single or with multiple
effectors, or specifically with the two proteins involved in formed the docking pore at the
tip of the needle complex.133 (Fig. Appendix II-4) Interestingly many of these chaperones
do not have directly homologous sequences across species but they still exhibit a highly
conserved tertiary structure.134 Structures of several TTS chaperones and effectorchaperone complexes have been determined using x-ray crystallography. The striking
feature of these structural studies is the high degree of conservation of the overall shape
of the fold as well as the identification of a generalized structural motif for effectorchaperone interaction that will help guide future research in this field.135-138 Questions
remain, however, regarding the interaction of full-length effector molecules with their
respective chaperones, as well as the nature of the TTSS secretion signal in general. The
results by Button et al. mentioned above as well as the general genetic organization of the
TTS chaperones all highlight the importance they play in the overall success of this mode
of virulence. In fact many of the questions that are actively being pursued in regard to
TTS systems – the global regulation of the apparatus, how the order of effector transport
is established and maintained, how is substrate specificity selected for – will almost
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certainly involve the role of the chaperone proteins as part of the answer.

Figure Appendix II-4.

Depiction as published by Page and Parsot of genes for

chaperones (light colors) and the secreted virulence factors they bind (corresponding dark
color) from several well-known TTS systems.133
What is known about TTS outlines a system that is amazingly complex and highly
evolved. Attempts to understand such a complex system at a mechanistic level, including
structural studies of the entire needle complex, highlight the degree of progress that has
been made in the state of the art of structural biology. More importantly, however, is the
degree to which TTS is essential to virulence and how an understanding of the effectors
of a particular bacterial species can reveal a tremendous amount of essential insight into
the pathogenesis of that organism. While the basal body, needle complex, and chaperone
delivery system are all highly conserved across bacterial species, the gamut of TTS
effectors and the effects they mediate as they are deployed in unique combinations by
each genus and species of bacteria reveals a great deal about mechanisms of bacterial
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virulence and adaptation. TTS allows bacteria to co-opt native host-cell pathways in
order to facilitate bacterial survival to the greatest degree possible. Studying how this
TTS-mediated reprogramming is accomplished not only elucidates mechanisms of
bacterial virulence but also highlights host-cell biochemical pathways in exquisite detail.
Quite amazingly many pathogenic bacteria express TTS effectors that are convergently
evolved to positively or negatively regulate eukaryotic signaling pathways. In addition,
the abundance of TTS in pathogens that cause significant human and agricultural disease
along with the above discussion about the very real prospect of exploiting TTS as a
drugable bacteriostatic target and, in a beautifully poetic manner, with the prospect of
utilizing TTS as a drug delivery mechanism all argue for the importance of a greater
understanding of this system. Below is a discussion of two projects aimed at
understanding TTS effectors SopB and YpkA from Salmonella spp. and Yersinia spp.,
resceptively.
Salmonella spp.
Salmonellae comprise a genus of gram-negative facultative anaerobic bacteria that are
intracellular pathogens in vertebrates. As of 2004, there are 2541 characterized serovars
distributed between two species, S. enterica (2419) and S. bongori (22).139 The host
specificity of salmonellae is highly variable with some serovars infecting various hosts,
while others are highly host specific. Furthermore, a given serovar highly pathogenic in
one host may be mild to asymptomatic in another. S. enterica serovar Typhimurium (S.
typhimurium), for example, is a common cause of enteric disease in humans and
agricultural animals, and is lethal in mice, while S. enterica serovar Typhi (S. typhi)
infects humans exclusively.
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Salmonellae spread between hosts via fecal-oral contamination, cause four types of
diseases – enteric fever (typhoid), enterocolitis/diarrhea, disseminated bacteremia, and
chronic asymptomatic carriage – and are a significant health concern for humans and
livestock.140 Globally an estimated 200 million to 1.3 billion cases of non-typhoidal
Salmonella infections occur annually resulting in 3 million deaths. Infections with S.
enterica serovar Typhi contribute an additional 17 million cases with 600,000 fatalities
annually, in spite of the presence of an effective vaccine. In the United States, the CDC
estimates that 1.6 million non-Typhoidal Salmonella infections occur annually resulting
in nearly 16,000 hospitalizations and 600 fatalities. Salmonella is the leading cause of
morbidity and mortality among bacterial food-born diseases in the U.S., with a combined
health and agricultural economic impact in 2007 of $2.5 billion.141 While enteric cases of
Salmonella are self-limiting, and bacteremia and typhoid are typically treatable with
antibiotics, the emergence of antibiotic resistant salmonellae continues to be an
increasing worldwide health risk. Cases of multi-drug resistance (MDR) have risen
significantly in the last 10 years due in part to the broad-scale prophylactic use of
antibiotics in animal husbandry and to the presence of a transferable genetic element in
salmonellae containing several drug resistance genes.142, 143 MDR salmonellae tolerate
ampicillin, chloramphenicol/florfenicol, streptomycin, sulfonamides, tetracycline, and 3rd
generation cephalosporins. Such isolates exist in at least 43 countries, are increasingly
associated with nosocomial outbreaks, and have been implicated in increased morbidity
and mortality.142-146
Pathogenesis
Salmonellae exhibit two essential virulence phenotypes necessary to establish local
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infection and promote disseminated disease: host-cell invasion and intracellular
pathogenesis. Salmonellae cause disease by invading otherwise non-phagocytic cells in
the host intestine, inducing inflammation, subsequently infecting attracted phagocytic
cells, and spreading systemically via lymphatic trafficking in phagocytic/antigenpresenting cells. Once introduced into the gastrointestinal tract, salmonellae adhere to
and induce phagocytosis in cells of the small intestine, specifically enterocytes, Peyer’s
patches, mesenteric lymph nodes, and newly identified cryptopatches or solitary intestinal
lymphoid tissue.147 Intracellular bacteria persist in a spacious phagosome that matures
into a structure known as the Salmonella containing vacuole (SCV). This structure
exhibits membrane markers of an early endosome and is able to evade trafficking to
lysosomal compartments. From within the SVC, salmonellae induce host-cell secretion of
IL-8 and pathogen-elicited epithelial chemo-attractant (PEEC), eliciting local
inflammation and attracting phagocytes. By an unknown mechanism, the SVC allows
salmonellae to traffic to and across the basolateral surface of infected cells where the
bacteria repeat the process of host-cell invasion in the newly-attracted phagocytic cells, a
stage that is essential for virulence.148 Once within phagocytic cells, salmonellae induce
secretion of mature IL1-β and IL-18, amplifying inflammation and inducing pyroptosis of
infected phagocytes by an intracellular caspase-1 mediated mechanism. While seemingly
paradoxical, the active proliferation of a proinflammatory environment appears to benefit
salmonellae by attracting migratory phagocytic cells, which salmonellae readily infect
and utilize for systemic spread, and by inhibiting competing and/or protective intestinal
fauna.149
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Salmonella Pathogenicity Islands
The majority of the genes necessary for the pathogenesis of salmonellae are located on
pathogenicity islands (SPI) distributed throughout the Salmonella genome. Twelve SPIs
are distributed differentially across Salmonella spp. and are perhaps most notable for the
presence of two type three secretion systems (TTSS) in SPI-1 and SPI-2, which are
critical for host-cell invasion and intracellular pathogenesis, respectively.150 Each TTSS
translocates a unique set of SPI-encoded effectors that are spread across the highly
conserved SPI-1, -2, and -5, which are found in all but one Salmonella spp.151, 152 The
temporal regulation of the SPI-1 and SPI-2 TTSS and their respective effectors allows for
a complex and highly orchestrated manipulation of host cell biology. These effectors
possess a variety of different functions that mimic or modify the host cell molecular
machinery such that a large number of cellular pathways are coordinately affected.153
Salmonella outer protein B (SopB, previously SigD)
SopB is one of five SPI-1 TTSS effectors necessary for the invasion phenotype in
Salmonellae and is found in all but one known subspecies, which lacks the SPI-1 TTSS
altogether.151-153 SopB is a phosphoinositol (PtdIns) phosphatase active throughout
invasion and intracellular phases of salmonellae infections.154, 155 SopB comprises 560
residues, with N-terminal chaperone binding and secretion signal domains, a
ubiquitinated domain (amino acids 29-116), a membrane association domain (a.a.117167), and three C-terminal PtdIns phosphatase homology domains.156, 157 (Fig. Appendix
II-5A) PtdIns are a major class of signaling molecules within the host cell and are
involved in the regulation of many cellular processes.158 The enzymatic activity of SopB
generates fluxes in the concentration at least four signaling PtdIns and has been shown in
!

109

a phosphoproteomic analysis to lead to be essential for nearly 50% of all cellular
phosphorylation events that occur within host cells follwing Salmonella invasion.159
These fluxes are the basis for at least five characterized effects within the host cell:160-162
i. AKT activation and anti-apoptosis: the synaptojanin (5-phosphatase) homology
domain at the C-terminus of SopB is required to activate AKT for 6-8 hours
post infection by generating PtdIns(5)P from PtdIns(4,5)P2.157, 163, 164
ii. Chloride secretion: the hydrolysis of pentakiphosphate to yield PI(1,4,5,6)P4
antagonizes the binding of Cl- channel inhibitor PI(3,4,5)P3, the effects of which
causes 50% of the fluid secretion in bovine ligated ilial loop models of
salmonellae infection.155, 165, 166
iii. Creation and maintenance of Salmonella Containing Vesicle (SCV): elimination
of PtdIns(4,5)P2 by SopB promotes membrane fission to create the spacious
phagosome and subsequent SCV, in which the high PtdIns(3)P content is
maintained by SopB thus preventing degradative lysosomal trafficking.167, 168
iv. Actin remodeling: SopB alters the actin cytoskeleton by activating RhoG via
SH3-containing guanine nucleotide exchange factor (SGEF), which is activated
by a flux in PtdIns of unknown identity. Additionally, SopB, SopE, SopE2, and
SipA disrupt tight junctions via Rho-family GTPase activation.169-171
Interestingly, SopB lacking C-terminal phosphatase domains has been reported
to disrupt actin polarization.172
v. CDC42 activation: SopB activates CDC42 in a phosphatase-dependent manner,
leading to actin-mediated cytoskeletal rearrangements.173 The interaction of
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SopB and CDC42 has been localized to SopB residues 1-142. SopB constructs
mutated to lack ability to interact with CDC42 do not traffic to the SVC, which
correlates with decreased rates of intracellular Salmonella replication within the
host cell.174 Curiously, phosphate-dead mutant (R468A) inactivated CDC42
when heterologously expressed in yeast, giving further potential evidence for a
phosphatase independent activity as mentioned above.175 The recent structure
of SopB 29-181 in complex with CDC42 gives further evidence for phosphatase
independent activity as it shows that SopB contains a guanine nucleotide
dissociation inhibitor (GDI) that recognizes the CDC42 GTPase binding
domain, thereby inhibiting CDC42 and preventing downstream signaling events
mediated though this pathway.176
Salmonella invasion gene E (SigE): SopB type III secretion chaperone
The structure of SigE has been solved crystallographically to 1.9Å resolution, and sitedirected mutagenesis of essential hydrophobic and electrostatic interactions has
demonstrated the diversity of interactions present in this particular chaperone-effector
pair.135, 137
Results
SopB (30-561) was successfully cloned from genomic Salmonella enterica serovar LT2
and expressed recombinantly in E. coli as a construct containing an N-terminal 6xHis-tag
cleavable with 3C protease. Various strategies were used to attempt to clone the full
length sequence including optimization of PCR cycles with gradient annealing, melting,
and extension protocols as well as with different polymerases; however none of the
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techniques were successful. Levels of SopB30-561 expression were unsatisfactory (<1
mg/ml) and yielded aggregated samples upon purification. A series of N-Terminal
truncations were created in an attempt to identify a more-soluble construct: 60-, 70-, 146, 170-, 185-, 200, and 259-561. (Fig. Appendix II-5 B) All constructs were created
successfully, but none exhibited increased solubility. Secondary and tertiary structure
prediction using PHYRE identified neither an obvious domain structure nor a structural
homologue that could assist the rational design of a more soluble construct.177
Co-expression of SopB 30-561 with SigE yielded a dramatic increase in SopB expression
and solubility (100-120 mg/L of cultured cells and >80 mg/ml for purified protein,
respectively), which allowed for purification of SopB in complex with SigE to high
purity for crystallization screening. The SopB:SigE complex was very stable such that
attempts to separate the two proteins were not successful using native buffer conditions,
including both anion and cation exchange chromatography. Sparse matrix crystallization
screening of this SopB30-561:SigE complex at both 15 and 31 mg/mL at both room
temperature and at 4°C yielded two hits in 96-well format at 4°C (50% MPD, 200 mM
Am. Phosphate, and 100 mM Tris pH 8.5; and 25% Tert-butanol, 100 mM Tris pH 8.5).
(Figure SoPB 1 G-H) Multiple attempts to reproduce these crystals in 96- and 24-well
format in both sitting and hanging drop failed to reproduce the initial crystal hits.
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Figure Appendix II-5. Initial purification and crystallization of SopB. A. Schematic of
SopB showing the key features of the protein including a region of shown to be
ubiquitinated, a membrane association region (also CDC42-interaction domain), and
phosphatase domains. * denote sites of proteolysis (see panel F) B. Representative
Superdex 200 gel-filtration elution profile for SopB 30-561 and all other constructs
shown in panel C. Note that nearly all protein elutes at 40-42 mL, which is the void
volume for the column.

C shows schematic of all constructs tested for SopB

overexpression. None improved stability. D. 6xHis(3C)SopB 30-561 before (right) and
after (left) 3C proteolysis to remove 6x-His purification tag. E. Final gel-filtration
purification step of SopB30-561/SigE-fl showing that a large majority of the material
remains in complex with compliment and that few contimanants were seen. F. Limited
proteolysis of SopB30-561 w. SigE.

Triangular shape shows the concentration of

Subtilisin. Red arrows indicate bands sent for N-terminal sequencing, and the confirmed
sites of proteolytic lesions are indicated by (*) in panel A. G and H show initial crystal
hits from primary round of screening. G. Initial crystal hit condition 50% MPD, 200mM
Am. Phosphate, 100 mM Tris pH 8.5 H Initial crystal hit condition. 25% Tert-butanol,
100mM Tris pH 8.5.

!

113

!

114

Other purification options were attempted for SopB in complex with SigE to yield the
best possible crystallization material, but nothing yielded results that were objectively
better than the results described above. The one exception to this statement was the use
of ultracentrifucation prior to final gel-filtration purifiction. (figure UUIOP). While gel
filtration offered a clean means by which to separate soluble aggregates from monodisperse soluble material, ultra-centrifugation (80,000g for 60 minutes at 4°C)
accomplished the same level of purification without gel filtration, and could therefore
also allow a cleaner starting material before the final gel-filtration polishing steps. It
seems that this step could easily apply as a general purification step for crystallization
samples and should be considered for future projects. In this project it did not provide
any different results and crystallization screens of ultra-centrifuged material yielded
similar results to the previous trials.

Figure Appendix II-6

Purification of SopB30-561/SigE complex via ultra-

centrifucation (80,000 xg). Gel filtration of the pre-(B) and post-centrifucation (A)
samples. Note the large void peak in B that is completely removed by centrifugation, as
shown in A. C SDS-PAGE of samples from the middle of the elution curve from the preand post-ultra-centrifuge.
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Having failed to obtain reproducible crystals with SopB30-561 in complex with SigE,
several residues of SopB that were predicted to be surface exposed and to contribute
significantly to surface entropy have been mutated to alanine to determine if these
regions were inhibiting crystal formation.178 The resulting constructs SopB118121AAAA, 256-257AA, and 312-313AA were characterized, but also failed to yield
positive crystal hits.
Further attempts were made to identify a stable SopB construct that could be expressed in
the absence of SigE. Limited proteolysis of the SopB30-561:SigE complex with
increasing concentrations of subtilisin did not reveal definitive results as would be
characteristic from a multi-domain protein, i.e. the banding pattern of the degradation
products did not reveal fragments that were clearly stable over a range of subtilisin
concentrations. Edman sequencing of the degradative products identified cleavage at
residues 53, 229, and 360. (Fgure sopB-1 A and F) As several constructs from the initial
round of N-terminal truncations had already characterized constructs that were similar to
these results, the proteolysis results did not offer significant progress. Cleavage at
residue 360 was in the middle of the putative PtdIns(4)P phosphatase domain, so this
residue was not used for construct design. Instead, residue 229 was used as a basis for
two additional constructs, 229-561, and 229-505, both of which yielded negative results.
Reductive alkylation of the SopB30-561:SigE complex was used to further expand
possible crystallization conditions. Interestingly, gel-filtration and anion-exchange
purification steps following reductive alkylation of the complex resulted in a clean
separation of the two proteins. (Figure 2 SopB A-D) Purified thusly, reductively
alkylated SopB 30-561 (RASopB 30-561) was screened by spare-matrix crystallization
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screening at 10-12 mg/mL at both room temp and 4°C with no identified hits. A sample
of reductively alkylated RASopB was also sent to the Hauptman-Woodward Medical
Research Institute for high-throughput crystallization screening using a 1536-well
crystallization screen designed for membrane proteins.179 These screens yielded several
crystallization hits that were optimized in 96-well format in-house around the following
conditions: 1.1 and 2.2 M CaCl2 in 100 mM Na-Acetate (pH 5.9), HEPES (pH 6.8), and
Tris (pH 7.4). (figure sopB 2 F) UV microscopy of these hits suggested they were
protein containing crystals and optimization was extensively pursued including multiple
formats, micro and macro seeding, and additive screening, which identified T-butanol as
an additive that promoted cleaner crystal edges, decreased nucleation, and increased
crystal growth.180 After multiple failed attempts to optimize these crystals to diffractionsized samples (the largest crystals remained well under 25 µm), it was noted that older
trays had begun to grow crystals in the well solution, i.e. not in the experimental drop,
and thus could only be salt crystals. The crystal morphology of the well crystals matched
the morphology in the drop with the almost certain conclusion that the crystals being
optimized were salt. This conclusion was suspected originally due to the presence of
Ca2+ ions as the sole precipitant at two very different concentrations with almost identical
crystallization results. Calcium, being a divalent cation, has been found empirically to
readily form salt crystals in a variety of crystallization conditions. The chemical basis for
this behavior likely stems from the low solubility of many salts formed by divalent
cations, which, interestingly is also the basis for the presence of divalent cations in the
most common forms of kidney stones. This limited solubility has prompted many
commercial crystallization screens to limit the inclusion of divalent cation reagents due
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the high false-positive rate that such conditions give in crystallization screens.181
Given that the RA-SopB30-561 was able to be purified away from SigE, another round of
limited proteolysis was attempted to determine if the lack of SigE would present a
different digestion pattern and possibly suggest a more consildated domain architecture
or at least additional proteolysis sites that could be useful for future expression trials.
Unfortunately, the digestion patters were similarly problematic to those seen for SopB30561/SigE. The banding pattern upon degradation did not yield a small number of stable
domains and instead yielded many bands that seemed fairly unstable even over a narrow
range of subtilisin concentration. (Fig. Appendix II-5F)
Due to the large number of lysine residues in SopB (50), it was possible the results of
reductive alkylation yielded a highly heterogenous population of SopB molecules that
would not be favorable for crystallization. Consequently separation of the SopB30561/SigE complex was attempted using affinity chromatography under denaturing
conditions followed by on-column refolding. This protocol yielded purified SopB30561(Figure UIOUPO); however, the refolded SopB was not stable and quickly
aggregated, suggesting that SigE does stabilize a domain that is inherently unstable in the
absence of a chaperone or modification by reductive alkylation.
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Figure Appendix II-7 Purification and crystallization of reductively alkylated SopB 30561.

A. SDS-PAGe analysis of Superdex 200 gel-filtration purification (C) of

reductively alkylated SopB 30-561 from SigE. B. SDS-PAGE analysis of SourceQ anion
exchange purification (D) of reductively alkylated SopB30-561. E. SDS-PAGE of eluted
fractions from Ni-NTA of on-column refolded SopB30-561 showing separation from
SigE during refolding. F. Initial crystal hits (far right, bright field on bottom, UV in top)
of high throughput crystallization screen for reductively alkylated SopB30-561.
Optimized crystals are shown in polarized brighfield with ruler marked in micro meters.
The crude extent of the domain in SopB that binds to the SigE chaperone was
investigated by co-expressing SigE with the series of N-terminal truncations mentioned
above. Favorable interaction of SigE with SopB was observed indirectly through
increases in SopB expression and directly through co-purification of SigE with SopB:
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constructs 70-561, 146-561, and 170-561 co-purified with SigE but constructs 185-561,
200-561 or 229-561 did not. This experiment confirmed that SigE interacts with the Nterminus of SopB and that the C-terminal limit of the SigE-association domain is
somewhere between residues 170-185. (Fig. Appendix II-8) The following C-terminal
truncations of this domain were co-epressed with SigE in an attempt to identify the Nterminal limit of the region that was critical for successful co-expression of SigE and
SopB: SopB 30-229, 30-185, 30-170, 30-145, 30-110, 53-229, 53-185, 53-170, and 53145. All of these constructs co-expressed well with SigE (data not shown). Together
these data suggested that a SigE-association domain resides in the N-terminus of SopB
and can is completely contained in the SopB30-185 construct.
The assertion that the above experiments identify the minimal SigE-association domain
in SopB assumes that the condition of successful co-expression offers a read-out
forassociation. Given that SigE is known to function as a SopB chaperone, this does not
seem like an unreasonable assumption, but it is certainly possible that additional
interaction between SigE and SopB could exist outside of this domain and that such an
interaction could have significant functional significance. Following the belief that the
most “crystallizeable” protein constructs are often those that contain the minimal extent
of the domain of interest, structural studies were pursued for SopB 30-185 in complex
with SigE.
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Figure Appendix II-8. Identification of SigE binding domain in SopB. Schematics
represent constructs that were characterized for coppurification with SopB. The top set
of schematics show N-terminal truncations that identify the C-terminal limit of the SigE
binding domain, for which the SDS-PAGE analysis Ni-NTA purifications of His-tagged
SopB constructs co-expressed with untagged full-length SigE. The numbers along the
bottom of the gel correspond to the N-terminal residue of the construct. The bottom two
groups of schematics show C-terminal truncations of SopB, which were designed to
identify the N-terminal boundary of the SigE binding comain. All of these constructs
purified with SigE (data not shown), so the N-terminal border of the SigE binding
domain is not absolutely clear, but is assumed to be somewhere between 30 and 110.
SopB 30-185 was co-expressed and purified successfully in a manner similar to SopB30561 utilizing a 3C-protease cleavable 6xHis tag on the SopB construct with rounds of NiNTA purification pre- and then post 3C digest, with subsequent gel-filtration purification.
(figure panel A) The yield of 12L of culture was concentrated to 13.6 mg/mL for the
purposes of crystallization screening. SDS-PAGE analysis of the concentrated sample
indicated that SigE had progressively been lost during the purification leaving behind
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what appeard to be SopB30-185 alone. Trace bands of lower molecular weight than
SopB30-185 and of appropriate molecular weight for SigE were noted and Edmun
sequencing was performed to determine whether SigE was still present in a decreased
ratio or whether the smaller molecular weight bands represented breakdown/proteolysis
of SopB30-185. (figure UIOPSUD panel B). A total of four separte sequencing samples
were sent and all were found to have the N-terminal sequence of SopB, indicating that
SigE had been lost during purification and the banding on the SDS-PAGE of the
concentrated sample represented C-terminal truncations of the SopB30-185 construc.
This result was interesting since it suggested that SopB30-185 was only soluble when coexpressed with SigE but was stable in the absence of SigE thereafter. Moreover, unlike
SopB30-561, the affinity between SopB and SigE seems to be diminished when only the
minimal SigE-association domain is expressed since the full-length constructs could
never be separated by gel-filtration or anion exchange wherease the SopB30-185
construct was separated with gel-filtration alone. This last observation somewhat calls
into question the deliniation of SopB residues 30-185 as the only SigE interaction domain
described above.
The material obtained from the steps above was sent for high-throughput crystallization
screening at the Hauptman-Woodward Medical Research Institute mentioned above for
RA-SopB30-561. Several conditions yielded positive hits, with all showing a similar
sea-urchin morphology of clumps of fine needles with a dense core. Bright-field and UV
images gave strong evidence that the crystallized material was proteinaceous. (figure
SHJDF panel C) The conditions were reproducible in-house in 96-well format and
several methods of optimization were employed, including micro-seeding and additive
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screening, which identified several conditions that maximized the fine needle growth and
limited the central clumps. The best of these efforts is shown in figure OSDFSDFIOP
panel D; however, these images also show the limit of optimization that was achieved
with these conditions. Ultimately the optimized crystals were still only 25-50 µm in
length and immeasurably thin, which precluded any assessment for diffraction on the inhouse x-ray source.
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Figure Appendix II-9. Crystallization trials of SigE binding domain of SopB in complex
with SigE. A. SDS-PAGE of final purified sample of SopB30-185 used for crystal
screening. A sample of SopB30-561 with SigE is run alongside for comparision and to
demonstrate a notebable lack of SigE band in the SopB30-185 sample. B. PVDF
membrane showing several different concentration so of SopB30-185 used for crystal
screening analyzed for Edmen sequencing.

Bands labeled 1-4 were excised and

sequenced and all four had the N-terminal sequence of SopB30-185, confirming the
absence of SigE from these samples. C. Crystal hits from high throughput screening of
SopB30-185 sample shown in A. Left strip shows progression of crystal growth and three
imaged on right show, from top, higher quality bright field (BF), uv (UV), and color
bright field (BFc) images of this condition after 4 weeks: 400 mM Magnesium Chloride
Hexahydrate, 100 mM MES pH 6.0, 30% PEG 3350 (w/v). D. Two images of optimized
crystallization conditions form high-throughput screen in C that contain the additive
benzamidine HCl. The longest needles in D are approximately 25 micrometers long.
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Discussion
The ability to explore the structural biology of SopB was consistently hampered by the
inability to obtain high-quality, reproducible crystals of SopB either alone or in comples
with its TTS chaperone SigE. Initial difficulties of low yield and aggregative behavior
were solved successfully through co-expression with SigE and through the use of
reductive alkylation. Both approaches yielded high-quality, non-aggregating material
that seemed optimal for crystallization screening. The behavior of SopB when coexpressed with SigE showed an extremely stable complex that remained in all but
denaturing conditions. Empiric construct design in the context of SigE co-expression
allowed the identification of a minimal region comprising residues 30-185 of SopB that
was necessary and sufficient for soluble expression with SigE, but further rounds of
purification resulted in a pure sample of SopB30-185. The depature of this result from
the behavior of the SopB30-561/SigE complex was interesting as it suggested that SigE
plays an important role in stabilizing and solubilizing the growing translated SopB, and it
also suggested that additional contacts outside of the 30-185 could contribute to the
interaction between SopB and SigE thus reinforcing this interaction in the full-length coexpression. These results are further interested as recent articles have been published
identifying a minimal CDC42-interacting domain. The interaction of SopB with CDC42
has been shown to contribute to the overall successful invasion of Salmonella into the
host cell but the SopB CDC42 interaction seems independent of the phosphatase activity
of SopB. The identified CDC-42 interaction domain of SopB maps very closely to the
minimal SigE-interaction domain described above. The interaction of the N-terminus of
SopB and CDC42 has also recently been shown crystallographically.176 Again, these
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results strengthen the conclusion from the above experiments that SopB30-185 represents
a sub-domain of the protein that exhibits an innate level of stability and also functions via
protein-protein interaction to help affect bacterial invasion. Unfortunately none of the
crystallization screening hits yielded material that was productive in generating
diffraction data. There are still many questions regarding the structural biology of SopB
that remain to be answered and further research into this TTS virulence factor will
definitely be an interesting to topic to follow for many upcoming years.
Yersinia spp. and YpkA
Yersinia are genus of Gram negative rod-shaped bacteria that contain three important
human pathogens: Y. enterocolitica, Y. pseudotuberculosis, and Y. pestis. The first two of
these species cause acquired food-borne illness that results in a spectrum of disease
ranging from acute to chronic gastro-enteric infection with septicemia in advanced cases.
These infections are typically self-limiting in healthy individuals but can result in
hospitilzation and even death in the young, elderly, and immune compromised.182 Y.
enterocolitica is by far the most common of the two food-borne species and is typically
associated with undercooked pork and unpasteurized milk products.
The far greater interest in this genus stems from the significant influence on human
history exerted by Y. pestis. Transferred between mammalian hosts via a flea vector and
spread from host to host via flea bite, Y. pestis is the causative agent of pneumonic,
septicemic, and most famously bubonic plague. The significant prevalence of this
bacterium throughout the world was first appreciated in the late 1890s by Alexandre
Yersin, a disciple of Koch and Roux, who isolated the bacterium during an outbreak of
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the plague in Hong Kong. Yersin went on to study the bacterium extensively throughout
Asia and developed an antisera to Y. pestis that dramatically increased survival, which
prompted in the mid 20th century the renaming of the genus in his name.183 While some
controversy has surrounded the attribution of the great plagues of human history to Y.
pestis alone, genetic testing has confirmed evidence of the organism in isolates from two
significant instances of pandemic plague that took the lives of millions of people
throughout Europe and Central Asia in 1347 and 1353.184 Y. pestis has without a doubt
had one of the most profound influences on human history of any infectious organism;
moreover, the specter of Y. pestis infection has gone from bad to worse during many
historical periods as this pathogen has time and again been utilized as a biological
weapon in almost every corner of the globe.185 This latter threat combined with the
persistent endemic nature of the disease in all continents except Australia and Antartica
continues to prompt extensive research into this organism as new means of rapidly
detecting and effectively treating infections caused by this organism are in constant need
of attention.
Unlike Salmonella spp. the TTS virulence system of Yersinia spp. is located on a
virulence plasmid that, although different between the three Yersinia species, is highly
conserved with regard to the virulence factors encoded therein. TTS is not the only
mechanism of virulence in Yersinia, but the combined effect of the six main TTS
virulence factors in Yersinia, named Yersinia outer proteins (Yop), has a significant
influence on the pathogenicity of disease.186 The concerted effect of the various Yops is
to suppress and reorient the host immune response, effecting critical immune surveillance
mechanisms, particularly the phagocytic behavior of macrophages. The suppression of
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monocytic phagocytosis of Pasteurella pestis (now known as Y. pestis after Yersin) was
first documented in 1969 by Cavanaugh and Randall.187 Further evidence of extracellular
multiplication of Y. pseudotuberculosis was shown by electron microscopy by Simonet et
al. in 1990 only in bacteria harboring the Yersinia virulence plasmid, which has
subsequently been shown to contain the complete TTS and attendant virulence
effectors.186, 188 The net result of the Yop family is to suppress bacterial internalization by
phagocytic cells and to promote extracellular replication in an environment free of hostimmune surveillance.
Yersinia protein Kinase A: YpkA
YpkA is 730 residues long and was identified as one of the first Yop (also known as
YopO) proteins nearly 20 years ago when it was first recognized as a secreted Ser/Thr
kinase indispensible to virulence.189 Initially a substrate for YpkA was not known, but
while that search continued, YpkA was subsequently found to interact with the Rho
family of GTPases,190-192 an activity that was found to correspond to an inhibition of actin
function within the host cell that was independent of the Ser/Thr kinase activity of
YpkA.193 Interestingly, YpkA has also been shown to interact with G-actin (non-muscle
actin) strongly enough to inhibit actin polymerization at both the extreme C- and Nterminal ends of the YpkA protein and that actin binding is necessary and sufficient for
kinase activation in YpkA, which in the absence of actin is otherwise kinase-inactive.69
The interaction between actin and YpkA is interesting as the essential domains for Gactin binding are removed by 200-300 residues from the actual kinase domain of the
protein. No structural biology of the entire protein has been published to date, but an
exceptional characterization of the inhibitory activity of YpkA on the Rho family of
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GTPases was the product of a prior graduate student in the Stebbins lab, Gerd Prehna.194,
195

In his graduate work Dr. Prehna demonstrated that a 200 residue C-terminal domain

of YpkA constitutes a GDI domain that inhibits members of the Rho family of GTPases.
It has also recently been shown that a target for the kinase activity of YpkA is Gαq,196
which together with Rho GDI activity both explain how YpkA activity could disrupt
cytoskeletal function in host cells. Secondary effects from YpkA-mediated dysfunction
of cellular pathways include actin polymerization inhibition leading to decreased Fc-γ
recepter internalization and inhibition of Gαq, which has been purported to contribute to
the profound bleeding phenotype of Y. pestis plague.197, 198 While a significant amounts of
structural characterization for both the GDI and kinase activites of YpkA have been
published, there remains a large gap in the understanding of the kinase domain function
in YpkA. How actin interacts with and modulates the kinase activity is a very interesting
question as well as a very unique biochemical activity that has not been observed in the
literature outside of YpkA.
Prior work by Gerd Prehna to identify the sub-domains of YpkA had determined that a
domain containing the kinase motif of YpkA was contained within residues 115-428.
Once identified this domain was initially screened for crystallization without success.
Additionally two compounds had been identified using a high-throughput screening
protocol to determine molecules that increased the stability of YpkA in solution. The
basis behind the screen for these small molecules empirically tested the Tm of YpkA in
the presence of each of a large number of small molecules. Positive interactions that
increased the stability of the YpkA construct were identified by an increase in the Tm of
the YpkA-ligand complex above the baseline Tm for YpkA alone. This screen identified
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two compounds that were then used for later crystallization trials described below:
demnacanthal and quercetin dihydrate. Studies have demonstrated a strong correlation
between increased stability of protein constructs (as measured by Tm) and successful
crystallization by vapor diffusion, and it was believed that use of the molecules identified
in the melting-temperature screen would do the same for YpkA.199

Figure Appendix II-10. Induction and solubility trials of C-terminal truncations of
YpkA kinase domain. For each construct three lanes are shown indicating un-induced
cells (U), the induced soluble fraction (iS) and the induced insoluble/pellet fraction (iP).
Initial attempts to identify the minimal soluble kinase domain of YpkA were not terribly
enlightening as they confirmed the 115-428 construct that had already been partially
characterized previously by Dr. Prehna in his graduate studies was the most likely
minimal domain (Fig. Appendix II-10). N-terminal truncations from 115 were not
attempted as the secondary structure prediction of full-length YpkA showed that residue
115 was at the beginning of a stretch of amino acids with a very high probability to form
an α-helix. Instead empiric C-terminal truncations were made to determine whether a
shorter construct could be identified. In total 5 constructs were tested for soluble
expression (115-405, -410, -415, -420, and -426). All five over-expressed well but were
found exclusively in the insoluble fraction following cell lysis. (Fig. Appendix II-10)
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Once the minimal domain had been established, crystallization studies were pursued on
YpkA 115-428 as the optimal kinase domain construct.
Purification of YpkA 115-428 was very successful, with results similar to the prior work
of Dr. Prehna mentioned above; however, given the initial inability to crystallize this
domain, several different approaches were utilized as described below. Briefly YpkA
was overexpressed recombinantly in E. coli with a 3C-protease cleavable 6x-His
purification tag. Upon initial purification over Ni-NTA, the 6x-His tag was cleaved and
purified away from the 115-428 constructs by a second round of Ni-NTA purification.
Subsequent purification steps included FPLC gel-filtration followed by ion-exchange
chromatography. Interestingly, when this purification protocol was followed, the
homogeneous material obtained from gel-filtration separated into two discrete peaks on
anion exchange chromatography. (Fig. Appendix II-11A) Likely a result of a posttranslational modification of at least two different sites, the specific chemistry behind the
separation of these peaks was not explored much further. The two peaks were designated
“early” and “late” and repeat purification steps showed that the nature of the chemical
difference between these two populations of YpkA 115-428 was stable, i.e. following the
first round of anion exchange, the “late” peak could be passed over gel filtration again,
re-concentrated, purified over anion exchange a second time, and would still elute as a
single “late” peak. Reductive alkylation of YpkA 115-428 prior to anion exchange
eliminated the division of the protein into two populations (not shown) and would instead
yield a single peak. This result simply demonstrates that whatever the modification
causing the different behavior of the native YpkA 115-428 on anion exchange, it could be
reversed by the chemistry involved with reductive alkylation. Experiments such as mass!
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spec analysis or empiric treatment with phosphatases and glycosylases to attempt to
reverse the modification were considered but not pursued. With respect to the discussion
of Tm above, it could be highly productive to revisit these results to assess the Tm of the
early vs. late vs. reductively alkylated populations to assess which, if any, would be most
likely to crystallize. SDS-PAGE of these three samples – RA-YpkA, 115-428, “early”
YpkA 115-428, and “late” YpkA 115-428 – did not show an appreciable difference in the
constitution of these samples with regard to purity or degradation kinetics, so any
differences between these samples would be more chemical in nature and could have a
great deal of influence on cryatallizeability. (Figure Appendix II-11B)

Figure Appendix II-11. Anion exchange chromatography of YpkA 115-428. A. Elution
profile of YpkA 115-428 from SourceQ (GE Scientific) using FPCL. B. SDS-PAGE of
final purification of three samples of YpkA 115-428 used for crystallization screening.
RA is reductive alkylation (left two lanes), E (“early”) middle two lanes, and L (“late”)
right two lanes. The left lane of each of the three pairs was loaded with 10 µl of protein
sample, the right lane of each pair loaded with 2 µl of sample.
Reductively alkylated, “early”, and “late” YpkA 115-428 samples were screened for
crystallization using sparse matrix screening reagents as above for SopB; however, no
significant hits were observed for these samples in-house. Also as with SopB above,
samples were submitted for 1536-condition high throughput screening at the Hauptman!
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Woodward Medical Research Institute. YpkA is predicted to be a cytosolic protein and
specifically not membrane-assocaited, so the screens used were a non-membrane protein
crystalliztion formulation. RA YpkA 115-428 (20 mg/ml) sent for high-throughput
screening yielded only negative results. Similarly negative results were seen for “early”
YpkA 115-428 (20 mg/ml) with 1 mM of either of the two stabilizing compounds
mentioned above. Finally, attempts to co-crystallize YpkA 115-428 AMP-PNP (a nonhydrolyzable ATP analogue) were also pursued at the high throughput facility.
Magnesium was included in the initial crystallization mix with AMP-PNP as ATP
binding is often Mg2+-dependent. This screen yielded a variety of crystallization hits
(Fig. Appendix II-12 A), but close inspection revealed identical crystal morphology
across a variety of crystallization conditions. Moreover, all the crystallization conditions
of the screen that gave positive hits for YpkA 115-428 with Mg2+ and ATP had some
form of phosphate. Like the examples above in SopB with divalent calcium, these results
raised a very high suspicion that all the positive results were false-negative salt crystals
likely of magnesium phosphate, which has a solubility constant that is six orders of
magnitude lower than the original MgCl2-hexahydrate that was originally used to
introduce Mg2+ ions into the crystallization mix. These suspicions were clearly
confirmed by UV microscopy, which showed crystals completely transparent to UV light.
(Fig Appendix II-12 B and C)
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Figure Appendix II-12. High-throughput crystallization screening of YpkA 115-428
with Mg2+ and AMP-PNP. Characteristic positive hits for this screen are shown in A.
Panels B and C both show three views of the same hit showing, from left to right, grayscale bright-field, ultraviolet, and color bright-field views of the well.

Note UV

microscopy detects proteinaceous crystalline material. Clear images as shown in B and C
indicate salt crystals, in this case likely due to the presence of the Mg2+.

B shows a

condition containing 50% PEG/Tascimate pH 6.8 (Hampton) and 50% of the following
mixture:

0.25%

w/v

1,2-Diaminocyclohexane

sulfate,

0.25%

w/v

1,4-

Cyclohexanedicarboxylic acid, 0.25% w/v Methylenediphosphonic acid, 0.25% w/v
Sulfanilic acid, and 0.02 M HEPES sodium pH 6.8. C shows a condition containing
Sodium dihydrogen phosphate, Potassium dihydrogen phosphate, Na- HEPES pH 7.5,
and 25% (v/v) Glycerol-anhydrous.
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Several additional strategies were chosen to pursue structural information of the YpkA
kinase domain. The first of which was to consider crystallization of a much larger
construct, the second and third involved crystallizing YpkA in the presence of additional
proteins known to associate with YpkA with the hypothesis that a protein complex could
be more stable and thus more crystallizeable. Dr. Prehna had successfully crystallized
the C-terminus of YpkA in complex with Rac1, so the possibility was explored that the
inclusion of the C-terminal domain could stabilize the whole construct and results in
favorable crystallization. Furthermore, since the pervious structure of YpkA had been
accomplished as a complex with Rac1 crystallization screens were attempted with YpkA
115-731 that was purified with or without the co-expression of Rac1. These trials were
conducted using the Crystal Phoenix (Art Robbins Instruments) robotic crystallization
tool allowing a wide array of conditions to be samples in multiple drop:well ratios. No
significant hits were identified from these attempts. The potential results of a crystal
structure of the full 115-731 YpkA would provide interesting insight into the state of TTS
virulence factors as whole proteins as all the structures to date of this family of proteins
have been limited to single domains. It would also be of great significance to understand
how domains interact, particularly when the substrate for one domain – e.g. Rac1 in this
case – is bound. In this scenerio what does the other domain do/look like in the presence
of Rac1 binding. (Note, for all experiments listed above, the original cDNA used for
subcloning was the sequence originally cloned by Gerd Prehna for his thesis research and
comprised a YpkA gene numbered 1-731. For all experiments listed below, the YpkA
construct used for the actin binding experiments by Trasak et al. was kindly provided by
said authors).69
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As a means of pursuing these questions and in a manner similar to the above experiments
described for Rac1, the decision was made to attempt to co-crystallize YpkA in the
presence of actin. Stable YpkA-actin complexes that could be purified on gel-filtration
had been shown in the literature,69 and studies had shown that regions of YpkA interact
with actin.200 (see Fig Appendix II-13I) These experiments would require a source of
actin, and specifically non-muscle actin in the case of YpkA. The initial experiment to
produce a YpkA-actin complex involved co-expression of the human form of non-muscle
gamma-1 actin (hACTG1). A synthetic gene was produced using the cDNA sequence of
ACTG1 and codon-optimized for expression in E. coli. This construct was then coexpressed using a Duet two site expression plasmid with YpkA 89-729, the exact
construct that had been shown in the literature to form a complex with actin.
Unfortunately no co-expression of hACTG- was observed in these experiments as
detected by western blot analysis. (Fig. Appendix II-13A) Co-expression of hACTG1
with gelsolin, another actin binding protein, also failed to show significant actin
production. Actin has several unique post-translational modifications including a 3methyl-histidine at position 73 that is conserved across almost all known actin
homologues with the exception being some strains of yeast.201, 202 Perhaps for this reason,
for its polymer qualities, or for other unknown reasons it has historically been difficult to
recombinately express actin in any typical protein expression systems. Since there are no
simple sources of non-muscle actin, the first and most obvious step was the above
experiment despite the slim chance of success.
Non-muscle actin is more difficult to obtain in large quantities because, unlike muscle
actin, it is present at much lower levels in cells that express these actin iso-forms than the
!
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levels of muscle actin in myocytes. Cell types that utilize non-muscle actin do so to
dynamically alter cell shape and morphology. Mobile cell types such as macrophages
and neutrophils require non-muscle actin, and phagocytosis/endocytosis in endothelial
and neuronal cells similarly involve the focal polymerization of non-muscle actins.
Mobile unicellular organisms are also a prolific source of non-muscle actins, so model
systems such as Dictyostelium and Acanthamoeba are often used to study actin dynamics.
Various protocols exist for purifying non-muscle actin from these organisms, and an
interesting pull-down method of non-muscle actin purification from fibroblasts using
recombinant his-tagged Gelsolin has also been described.70, 203 Specifically, the YpkAactin binding studies by Trasak et al. mentioned above used Dictyostelium discoidium
actin. In the face of an inability to express non-muscle actin recombinantly, both of these
approaches – native expression from D. discoidium and Acanthamoeba as well as pulldown purification using 6x-his-Gelsolin and 6x-his-YpkA89-729 – were pursued as a
means of acquiring crystallization amounts of non-muscle actin.
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Figure Appendix II-13 Purification and complex formation of non-muscle actin with
YpkA. A. From left to right: initial purifications of non-muscle actin from D.
discoidium(two lanes), 30mM inidazole wash and 500 mM imidazole elution from NiNTA resin of ACTG1/Gelsolin coexpression, 30 mM imidazole wash and 500 mM
elution of ACTG1/YpkA89-729 coexpression. Panel is divided as follows: anti-Acin
Western (lower left), SDS-PAGE (upper-right), and overlay (upper left) of actin
purification. B. Pull-down purification of D. discoidium actin using his-tagged Gelsolin.
Panel divisions as in A. C. SDS-PAGE of eluted fractions from initial DE52 ionexchange purification of D. discoidium actin showing several actin-rich fractions
(prominent band). D. SDS-PAGE of final purified D.discoidium (Di) and Acanthamoeba
(Ac) actin. E.

Representative SD-200 gel-filtration elution profile for YpkA89-729

mixed with Acanthamoeba actin showing two elution peaks and no void peak, which
would be at ~8.0 mL for this column. F, G, and H. SDS-PAGE of eluted gel-filtration
fractions from mixtures of YpkA89-729 with D.discoidium (F), Acanthamoeba (G), and
Rabbit skeletal (H) actin. Notably no right-shift in the YpkA or actin profiles was seen,
and no complex formation was observed. I. Complex formation between YpkA 89-729
and D. discoidium actin as published by Trasek et al.69 A clear left-shift is seen in the
mixed sample, and fractions that contain both actin and YpkA are clearly seen.
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D. discoidium stock cultures were provided by Laura Macro of the Simon Lab at
Rockefeller and Acanthamoeba stock cultures were obtained from the ATCC and the
Mullins lab at UCSF. A plasmid containing the gelsolin construct described above was
kindly provided by Ohki et al. and used as an actin-binding pull-down reagent with actinrich lysates from Dictyostelium and Acanthamoeba with very limited success. Purified
gelsolin was added to cleared lysates of D. discoidium and Ni-NTA pull-down assays
were attempted; however, little to none of the original gelsolin was recovered (Fig.
Appendix II-13 A-B). The most likely explanation for these results was rapid
degradation due to high levels of protease in the cellular lysates. Similar results were
seen when using YpkA as a pull-down reagent (not-shown). Attempts to increase
protease inhibition were unsuccessful and ultimately this approach was abandoned for
plans to purify non-muscle actin biochemically from D. discoidium and Acanthamoeba
lysates.
Large volume cultures of D. discoidium and Acanthamoeba were grown without
significant difficulty and large-scale purification of actin was attempted using the
published protocol of Zuchero et al. for Acanthamoeba and also the unpublished protocol
used by Trasak et al. for their work with YpkA (personal communication, see methods).
Essentially both protocols use bulk anion exchange resin as a first pass purification step
for cleared cell lysates followed by rounds of polymerization, ultracentrifugation, and
depolymerization to yield purified actin monomers. While it was certainly the case that a
significant amount of actin could be obtained from these lysates and that fractions
containing enriched concentrations of actin were obtained from the initial anion exchange
purification steps, the subsequent purification steps proved difficult to execute
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successfully. (Fig. Appendix II-13 C). Whereas both protocols that were used stated that
polymerization post-anion exchange should yield readable visible polymerization of
actin, this was never observed in multiple purification attempts. Some material did seem
to polymerize, and an even small percentage of the pelleted polymerized actin would depolymerize, so the final yield from these attempts was frustratingly small but sufficient
for a few preliminary gel-filtration studies. (Fig. Appendix II-13D) Additional technical
difficulties included clogged ion-exchange columns and bacterial/fungal contamination in
dialysis/storage steps of the protocol. Alex Kelly of the Funabiki lab at Rockefeller
(formerly of the Mullins lab at UCSF) kindly obtained a sample of purified
Acanthamoeba actin from the Mullins lab to use as a standard and initial quality control.
(Fig. Appendix II-13D) Once monomeric forms of the two non-muscle actins were
prepared, YpkA89-729 was dialyzed into actin G-buffer and mixed with monomeric
actin. Complex formation was assessed by gel-filtration in a manner as consistent with
the protocol of Trasak et al. as technically possible. The one difference between these
studies and those published by Trasak et al. regard the size/volume of the gel-filtration
column. The published studies of YpkA-Actin complex formation used analytical scale
gel-filtration columns (3.2 x 300 mm SD200), which were not found to be available in
any lab that was contacted at Rockefeller, Memorial Sloan Kettering, and Cornell.
Instead a small preparative scale gel-filtration column was used that had significantly
higher bed volumes (30 x 300 mm SD200) and thus required a much higher sample
volume to achieve equivalent concentrations of proteins on the column. In personal
communication Trasak et al. reported they had successfully reproduced the experiment
with preparative scale columns, but direct data from these experiments was not available
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for comparison. Ultimately, attempts to reproduce the published binding results between
YpkA 89-729 and Dictyostelium non-muscle actin were unsuccessful, despite the use of
the exact same construct from the published results, the same source of non-muscle actin,
and nearly identical protocols. (Fig Appendix II-13E and F vs I). No left-shift in the
elution volume of either YpkA nor actin was observed, and co-elution of YpkA and actin
was not observed. The elution volumes of actin and YpkA were both appropriate for a
monodisperse species in solution suggesting that the buffer conditions were appropriate
to limit polymerization of actin and also were not unfavorable to YpkA solubility. These
negative results – i.e. no YpkA-actin complex formation – were again seen with
Acanthamoeba actin (an experiment predicted to be a second positive control) and with
rabbit skeletal muscle actin (an experiment designed to be a negative control). (Fig
Appendix II-13 G, and H respectively) There are many variables that remain to be
optimized in these experiments. First among them is the purification of actin from both
Dictyostelium and Acanthamoeba. The lack of clear polymerization of actin during the
purification process raises suspicions about the activity of the actin that was purified
originally. Strict adherance to the protocol was maintained at all times, but this is not to
say that some significant step is being overlooked either in execution of the steps of
purification or in preparation of reagents. Future collaborations with a lab that performs
these types of experiments regularly will be necessary for future work in this area.
Second is the significance of the size of gel-filtration column. It is clear from the
published data regarding YpkA-actin complex formation that only a fraction of the
material loaded onto the column forms a complex. This suggests that the affinity of the
complex between YpkA and actin might be relatively low and needs the high local
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concentration provided by the smaller diameter analytic gel-filtration to maintain a
population of the two proteins in a complexed state. It would be very interesting to know
whether the collected fractions that had both YpkA and actin would stay in complex
when ran again over the same column, or whether the dilution factor involved in this
experiment would ultimately cause dissociation of the complex. These are just a few of
the important questions that can be answered in a more robust and objective way once an
experimental protocol is established that is reproducible. Finally, having these reagents
prepared, i.e. monomeric actin and YpkA89-729, it would be possible to conduct an
entirely different set of experiments that were alluded to above regarding the interaction
of between the substrates of these multidomain virulence factors. Clear binding domains
for Rac1 and actin have been established for YpkA, but whether these two proteins can
bind YpkA at the same time is a question for which there is virtually no data. The
consequences of different binding affinities for these two substrates is very interesting to
consider as it could suggest that there is a “hard-wired” set of effects that YpkA will have
on the cell depending on the state of the cell at any given time. It could switch between
Rac1 inhibition if actin concentrations are low, but switch to actin-induced kinase activity
of Gαq if Rac1 is for some reason low or otherwise inhibited by other YpkA molecules.
How different affinities for different substrates would orchestrate the multitude of
downstream effects that are mediated by these molecules can only be speculated, but
having these tools in place could prove a valuable first step towards answering these
questions. Finally, the issue of attempting to purify and/or generate a complex between
YpkA and the substrate of its kinase activity remains a completely unexplored field. Gαq
has been clearly identified as a target of actin-activated YpkA kinase activity. Having
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purified actin, Rac1, and hopefully Gαq could add yet another level of complexity to the
above discussion that would shed valuable light on the integration of these various
signaling mechanisms mediated by YpkA inside host cells.
Summary:
Structural studies of the YpkA kinase domain remain in their infancy with attempts to
study the structural biology of the kinase domain experiencing very limited success to
date. The reasons for the lack of success are still unclear at this point. Multiple
approaches have been successful at generating soluble, well-behaved YpkA protein both
of a limited kinase domain and also of the multi-domain constructs. The success of the
YpkA GDI-domain structure in complex with Rac1 suggest that such approaches can
succeed provided the correct empiric combination of variables. There are many
questions that remain unanswered regarding the activity of YpkA as a whole – i.e. both
the GDI domain and the kinase domain together – as well as several important questions
about the mechanism of the kinase domain. Of particular interest is how recognition and
binding of actin at sites very remote by residue number to the kinase domain could
activate the activity of YpkA towards Gαq. The above studies outline several approaches
that will be pursued in the future.
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